<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20210" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Renal Cystic Disease</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Goksu</surname>
            <given-names>Suleyman Y.</given-names>
          </name>
          <aff>Mayo Clinic</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Leslie</surname>
            <given-names>Stephen W.</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Khattar</surname>
            <given-names>Divya</given-names>
          </name>
          <aff>Cincinnati Children&#x02019;s Hospital Medical Center, Cincinnati, OH</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Suleyman Goksu declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Stephen Leslie declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Divya Khattar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>23</day>
          <month>10</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20210.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Renal cystic disease is a term that refers to the group of pathologic conditions associated with the development of renal cysts. These conditions may present in children and adults with extrarenal symptoms and have genetic or non-inherited etiologies. The renal cysts caused by these conditions are some of the most common renal abnormalities and can vary from being clinically insignificant to resulting in end-stage renal disease. Different renal cystic diseases can be differentiated based on age of presentation, cyst size and characteristics, extrarenal symptoms, and family history.&#x000a0;This activity identifies the evaluation and treatment of the different varieties of renal cystic disease and highlights the role of the interprofessional team in evaluating and treating patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the key clinical features and risk factors associated with various renal cystic diseases, including autosomal dominant polycystic kidney disease (ADPKD) and less common cystic renal syndromes.</p></list-item><list-item><p>Apply evidence-based guidelines and diagnostic criteria for renal cystic diseases into clinical practice, ensuring timely and accurate diagnosis.</p></list-item><list-item><p>Implement appropriate management strategies, including surveillance, lifestyle modifications, and medical interventions, tailored to the specific renal cystic disease and its stage.</p></list-item><list-item><p>Facilitate seamless care transitions and continuity of care by coordinating referrals, follow-up appointments, and multidisciplinary consultations, optimizing patient outcomes and experiences.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20210&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20210">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20210.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Renal cystic disease (RCD) refers to a group of pathologic conditions associated with the development of renal cysts. These conditions may present in children and adults with extrarenal symptoms and have genetic or non-inherited etiologies. The renal cysts caused by these conditions are some of the most common renal abnormalities and can vary from being clinically insignificant to resulting in end-stage renal disease. The most common genetic RCD in adults is autosomal dominant polycystic kidney disease (ADPKD), a type of hepatorenal fibrocystic disease (HRFCD); the most common acquired kidney cyst is a&#x000a0;simple renal cyst.<xref ref-type="bibr" rid="article-20210.r1">[1]</xref><xref ref-type="bibr" rid="article-20210.r2">[2]</xref><xref ref-type="bibr" rid="article-20210.r3">[3]</xref>&#x000a0;&#x000a0;</p>
        <p>Renal cystic disease is typically differentiated and diagnosed by clinical features, such as patient age, symptoms, renal function, and cyst characteristics (eg, size, shape, location, and number).<xref ref-type="bibr" rid="article-20210.r4">[4]</xref><xref ref-type="bibr" rid="article-20210.r5">[5]</xref>&#x000a0;Diagnostic studies consist of renal imaging, laboratory tests, and genetic testing. Management typically involves supportive therapy, surveillance and treatment of complications, and, in some patients, transplantation.<xref ref-type="bibr" rid="article-20210.r1">[1]</xref>&#x000a0;</p>
        <p>Most renal cystic disorders are not well-known or understood by the general population. Therefore, patients and their families must receive adequate counseling and education to understand the particular disorder diagnosed as various rare cystic renal syndromes may have genetic implications.&#x000a0;Healthcare professionals should enhance their competence in evaluating, managing, and educating patients about renal cystic disease. Furthermore, clinicians should be empowered to drive positive changes, enhance patient safety, and improve overall care quality, enabling them to provide evidence-based and patient-centered care.<xref ref-type="bibr" rid="article-20210.r4">[4]</xref></p>
      </sec>
      <sec id="article-20210.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>RCD&#x000a0;comprises various underlying conditions&#x000a0;and is often classified as inherited or non-inherited (developmental dysplasia, de novo mutations, or systemic disorders). Advancements in research have led to a better understanding of the pathophysiologic causes of RCD. As a result, certain conditions can be categorized as dysplasias (encompassing abnormalities in renal structure) or ciliopathies (which involve mutations affecting renal tubular cilia). RCD usually has genetic etiologies; aside from ADPKD, most types first present in children or teenagers. The RCD most often&#x000a0;observed in adults is ADPKD.<xref ref-type="bibr" rid="article-20210.r6">[6]</xref></p>
        <p>
<bold>Inherited Renal Cystic Disease</bold>
</p>
        <p>Polycystic kidney disease includes the 3 forms below.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>ADPKD is one of the most common causes of adult-onset, end-stage kidney disease&#x000a0;caused by PKD1 and PKD2 mutations, which code for polycystin-1 and polycystin-2, respectively.<xref ref-type="bibr" rid="article-20210.r7">[7]</xref>&#x000a0;PKD1&#x000a0;is the more prevalent mutation, identified in approximately 85% of patients. It is associated with many extrarenal manifestations and has a 5% to 10% prevalence in the dialysis population.<xref ref-type="bibr" rid="article-20210.r3">[3]</xref><xref ref-type="bibr" rid="article-20210.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>Autosomal recessive polycystic kidney disease (ARPKD) is a rare ciliopathy caused by PKHD1 mutations that affects the fibrocystin-polyductin complex, a protein typically found in the&#x000a0;primary cilia and basal bodies of renal tubular cells, leading to hepatorenal fibrocystic abnormalities. It has a high perinatal mortality due to pulmonary hypoplasia and is associated with liver developmental abnormalities and hypertension.<xref ref-type="bibr" rid="article-20210.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>Glomerulocystic kidney disease&#x000a0;is primarily found in neonates and infants with a family history of PKD, but not all cases are associated with mutations in <italic toggle="yes">PKD1</italic>&#x000a0;or <italic toggle="yes">PKD2</italic>. This condition is associated with cyst formation in the glomerulus and increased Bowman's space due to gene mutations in renal tubular primary cilia or the centrosome. About 10% of cases are associated with mutations in <italic toggle="yes">HFN1&#x003b2;</italic>, and this phenotype results in hypoplastic kidneys with defects in the renal calyces and collecting systems. Of note,&#x000a0;<italic toggle="yes">HFN1&#x003b2; </italic>is thought to regulate transcription of <italic toggle="yes">PKD2</italic> and <italic toggle="yes">PKHD1</italic>.<xref ref-type="bibr" rid="article-20210.r5">[5]</xref><xref ref-type="bibr" rid="article-20210.r8">[8]</xref></p>
          </list-item>
        </list>
        <p><bold>Nephronophthisis:&#x000a0;</bold>Nephronophthisis is a&#x000a0;rare, autosomal recessive disorder that affects individuals at any age but is more frequently seen in children and young adults, leading to end-stage renal failure before age 30.&#x000a0;Nephronophthisis, the most common genetic cause of end-stage renal failure in the first&#x000a0;3 decades of life, results from mutations in various genes (eg,&#x000a0;<italic toggle="yes">NPH1</italic>&#x000a0;and <italic toggle="yes">NPH5)</italic>.<xref ref-type="bibr" rid="article-20210.r9">[9]</xref> The variants of this condition are further categorized based on the age of onset of ESRD. The most common variant is juvenile nephronophthisis, with an incidence rate of 9:8.3 million births. About 10% to 20% of cases are associated with extrarenal symptoms, including genetic syndromes like Senior-L&#x000f8;ken syndrome (associated with retinitis pigmentosa) or Joubert syndrome (associated with cerebellar vermis aplasia). Cysts are usually found attached to the collecting tubules rather than dissociated as in PKD.<xref ref-type="bibr" rid="article-20210.r5">[5]</xref><xref ref-type="bibr" rid="article-20210.r9">[9]</xref><xref ref-type="bibr" rid="article-20210.r10">[10]</xref><xref ref-type="bibr" rid="article-20210.r11">[11]</xref></p>
        <p><bold>Autosomal dominant tubulointerstitial kidney disease</bold> (ADTKD): ADTKD, formerly known as medullary cystic kidney disease, is a group of rare, autosomal dominant genetic disorders that have been recently reclassified due to mutations in multiple different genes. This classification is evolving but can be identified by ADTDK followed by the specific gene mutation (eg, ADTKD-<italic toggle="yes">UMOD</italic>). These mutations lead to misfolded proteins causing cytotoxicity, which leads to interstitial and tubular fibrosis. The most common mutation is in the <italic toggle="yes">UMOD</italic> gene. ADTKD presents as chronic kidney disease that slowly progresses to ESRD between the ages of 40 and 70. Extrarenal manifestations depend on the specific gene mutation and can include diabetes, gout, or neurodevelopmental delay. The kidneys are usually normal-sized initially but can shrink as disease progresses.<xref ref-type="bibr" rid="article-20210.r12">[12]</xref><xref ref-type="bibr" rid="article-20210.r13">[13]</xref></p>
        <p><bold>Cysts associated with tumor syndromes: </bold>These cysts, such as tuberous sclerosis and Von Hippel-Lindau disease, result from autosomal dominant gene mutations that exhibit variable penetrance. These are described in further detail in the history and physical section.<xref ref-type="bibr" rid="article-20210.r5">[5]</xref></p>
        <p>
<bold>Noninherited Cystic Kidney Disease</bold>
</p>
        <p>Noninherited RCDs can be due to developmental renal dysplasia, de novo genetic mutations, or acquired cysts from systemic disease. However, due to improved genetic analysis techniques, some etiologies in this group previously thought to be noninherited, eg, multicystic dysplastic kidney, have been found to have a genetic component likely. Most of these etiologies are considered to be largely a result of renal developmental malformations.<xref ref-type="bibr" rid="article-20210.r5">[5]</xref><xref ref-type="bibr" rid="article-20210.r14">[14]</xref>&#x000a0;Noninherited cystic kidney diseases include those discussed below.</p>
        <p><bold>Acquired cystic disease: </bold>This&#x000a0;occurs in patients&#x000a0;requiring dialysis and manifests as atrophic kidneys with microcysts. It is strongly associated with length of dialysis, and close to 100% of patients who are dialysis-dependent for longer than 10 years have this condition. The exact etiology is unknown but thought to be related to uremic toxins, kidney fibrosis, and calcium oxalate crystal deposition. Although usually asymptomatic, screening is recommended because these cysts are a significant risk of bleeding and renal cell carcinoma.<xref ref-type="bibr" rid="article-20210.r15">[15]</xref><xref ref-type="bibr" rid="article-20210.r16">[16]</xref></p>
        <p><bold>Simple renal cysts: </bold>Cysts that&#x000a0;typically&#x000a0;develop after the&#x000a0;age of 20 years and then increase in frequency as patients age. These are the most common RCDs, and autopsy studies show that 50% of those older than 50 years will have at least one renal cyst.&#x000a0;Simple cysts vary in size but, on average, are approximately 1&#x000a0;cm. The Bosniak classification system classifies cysts to stratify the risk of malignancy. As opposed to simple cysts, complex cysts may contain calcifications, septae, and loculations. The most common etiology of simple cysts is hypertension. The etiology is thought to be hypertrophy from localized ischemia or obstruction. Unless very large, simple cysts are usually asymptomatic and do not affect renal function.<xref ref-type="bibr" rid="article-20210.r5">[5]</xref><xref ref-type="bibr" rid="article-20210.r15">[15]</xref></p>
        <p><bold>Multicystic dysplastic kidney: </bold>This&#x000a0;condition occurs during fetal development when the nephrons and collecting ducts do not develop in one or both kidneys. The affected kidney has many noncommunicating cysts surrounded by nonfunctional renal parenchyma. About 70% of cases are unilateral; bilateral disease requires close observation for oliguria. About 30% of cases are associated with contralateral urinary tract complications, usually urinary reflux. Fortunately, this condition is usually benign and resolves itself by a median time of 10 years old.<xref ref-type="bibr" rid="article-20210.r17">[17]</xref>&#x000a0;There is a genetic component in some patients, and about 10% of cases are associated with mutations in the <italic toggle="yes">HFN1&#x003b2;</italic> gene.<xref ref-type="bibr" rid="article-20210.r5">[5]</xref><xref ref-type="bibr" rid="article-20210.r8">[8]</xref><xref ref-type="bibr" rid="article-20210.r18">[18]</xref></p>
        <p><bold>Medullary sponge kidney: </bold>This<bold>&#x000a0;</bold>is&#x000a0;characterized by cystic dilatation of the papillary collecting ducts, medullary cysts, nephrocalcinosis, and nephrolithiasis. Traditionally, this etiology has been classified as a spontaneous malformation; however, it may also have a genetic component, considering that it is associated with other developmental disorders and shows familial clustering. About 10% of patients will progress to chronic kidney disease (CKD).<xref ref-type="bibr" rid="article-20210.r19">[19]</xref><xref ref-type="bibr" rid="article-20210.r20">[20]</xref><xref ref-type="bibr" rid="article-20210.r21">[21]</xref></p>
        <p><bold>Rare miscellaneous abnormalities: </bold>These include isolated anomalies resulting in renal cysts, such as pyelocaliceal diverticula, unilateral renal cystic disease, and multilocular renal cystic nephroma.<xref ref-type="bibr" rid="article-20210.r5">[5]</xref><xref ref-type="bibr" rid="article-20210.r15">[15]</xref><xref ref-type="bibr" rid="article-20210.r22">[22]</xref></p>
      </sec>
      <sec id="article-20210.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The incidence of RCD depends on the underlying etiology.</p>
        <p>
<bold>Polycystic Kidney Disease</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>ADPKD is the most common RCD overall, with a prevalence of around 1 per 2500 persons, affecting 12.5 million worldwide, mostly adults.<xref ref-type="bibr" rid="article-20210.r6">[6]</xref><xref ref-type="bibr" rid="article-20210.r23">[23]</xref><xref ref-type="bibr" rid="article-20210.r24">[24]</xref>&#x000a0;ADPKD is also one of the most common causes of adult-onset end-stage kidney disease, with 50% of affected individuals progressing to renal failure by age 70 years.<xref ref-type="bibr" rid="article-20210.r6">[6]</xref>&#x000a0;ADPKD affects all racial and ethnic groups. Because of its delayed and indolent presentation, as many as 50% of affected individuals may go undiagnosed.<xref ref-type="bibr" rid="article-20210.r25">[25]</xref>&#x000a0;About 10% to 15% of affected individuals will not have a positive family history of the disease.<xref ref-type="bibr" rid="article-20210.r26">[26]</xref><xref ref-type="bibr" rid="article-20210.r27">[27]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>ARPKD is a rare ciliopathy with an incidence of 1 per 20,000 infants and a perinatal mortality rate of 30%&#x000a0; due to complications of pulmonary hypoplasia. In contrast to ADPK, the kidney is enlarged at birth, but around age 3 years, the kidney can start to shrink due to atrophy. ARPKD is primarily diagnosed in&#x000a0;infancy, childhood, or adolescence and is the cause of 5% of end-stage renal disease (ESRD) in children and adults.<xref ref-type="bibr" rid="article-20210.r6">[6]</xref></p>
          </list-item>
        </list>
        <p><bold>Nephronophthisis:</bold> This rare, autosomal recessive genetic disorder, with the most common variant being juvenile nephronophthisis (JNPHP), has an incidence of 98.3 cases per million births.&#x000a0;About 10% to 20% of children with JNPHP present with chronic renal failure, and between 1% and 5% of all affected patients ultimately need dialysis or transplantation. JNPHP is the most common cause of genetic ESRD in children.<xref ref-type="bibr" rid="article-20210.r5">[5]</xref><xref ref-type="bibr" rid="article-20210.r9">[9]</xref><xref ref-type="bibr" rid="article-20210.r10">[10]</xref><xref ref-type="bibr" rid="article-20210.r28">[28]</xref><xref ref-type="bibr" rid="article-20210.r29">[29]</xref></p>
        <p><bold>Autosomal-dominant tubulointerstitial kidney disease:</bold> The estimated population prevalence of this condition is 9 in 1 million births, and it tends to inevitably lead to renal failure later in life, typically between the ages of 30 and 60 years, with an average of 45 years.<xref ref-type="bibr" rid="article-20210.r30">[30]</xref><xref ref-type="bibr" rid="article-20210.r23">[23]</xref><xref ref-type="bibr" rid="article-20210.r31">[31]</xref><xref ref-type="bibr" rid="article-20210.r32">[32]</xref><xref ref-type="bibr" rid="article-20210.r33">[33]</xref></p>
        <p><bold>Cysts&#x000a0;related to tumor syndromes:</bold>&#x000a0;These conditions consist of autosomal-dominant gene mutations with an estimated incidence ranging from 1 in 6,000 to 1 in 10,000 births.<xref ref-type="bibr" rid="article-20210.r5">[5]</xref>&#x000a0;Von Hippel-Lindau syndrome has a reported incidence of 1 per 50,000 individuals.<xref ref-type="bibr" rid="article-20210.r15">[15]</xref></p>
        <p><bold>Acquired cystic disease:</bold> The occurrence of renal cysts is secondary to dialysis. The incidence increases in parallel to the number of years on dialysis and is more common in males.<xref ref-type="bibr" rid="article-20210.r5">[5]</xref><xref ref-type="bibr" rid="article-20210.r34">[34]</xref></p>
        <p><bold>Simple renal cysts:</bold> Typically, these cysts develop in adults, usually after the&#x000a0;age of 20 years, and then increase in frequency, occurring in 7% to 10% of the general populace. Incidence is associated with male sex, hypertension, and advanced age.<xref ref-type="bibr" rid="article-20210.r5">[5]</xref>&#x000a0;</p>
        <p><bold>Multicystic dysplastic kidney:</bold> Unilateral variants have a higher incidence, estimated to occur in 1 per 4300 births; bilateral kidney involvement has a reported incidence of 1 per 10,000 births.<xref ref-type="bibr" rid="article-20210.r18">[18]</xref></p>
        <p><bold>Medullary sponge kidney:</bold> The precise incidence of this etiology is unknown; however, between 3% and 20% of individuals with renal stones are estimated to have medullary sponge kidney.<xref ref-type="bibr" rid="article-20210.r19">[19]</xref><xref ref-type="bibr" rid="article-20210.r20">[20]</xref></p>
        <p><bold>Rare miscellaneous abnormalities:</bold> These cystic renal anomalies rarely occur, often with only a few cases reported worldwide. For instance, pyelocaliceal diverticula are identified in up to 0.6% of patients who have had an intravenous pyelogram performed.<xref ref-type="bibr" rid="article-20210.r5">[5]</xref><xref ref-type="bibr" rid="article-20210.r22">[22]</xref></p>
      </sec>
      <sec id="article-20210.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Due to the various etiologies underlying the development of RCDs, several abnormalities in renal function can result. It is believed that the primary physiologic abnormality in RCD is the loss of functional nephrons to cysts; this can be due to genetic mutations of renal tubular cilia (ie, ciliopathies), developmental anomalies in renal structure (ie, dysplasia), or acquired due to systemic factors.</p>
        <p>Primary cilia usually line renal tubules and project into the tubule lumen, contributing significantly to the kidney's normal physiologic function. Generally, kidney cysts develop from renal tubule segments and detach from the parent tubule after growing a few millimeters.&#x000a0;The fluid inside the early developing cysts is initially glomerular filtrate, but as the tubules dilate and separate from the nephron, the cystic fluid is actively secreted. Therefore, ciliopathies (eg, polycystic kidney disease,&#x000a0;nephronophthisis, and&#x000a0;ADTKD) are believed to be associated with abnormal proteins and gene mutations that result in renal tubular&#x000a0;ciliary mechanosensors becoming unable to detect luminal flow rates.<xref ref-type="bibr" rid="article-20210.r35">[35]</xref><xref ref-type="bibr" rid="article-20210.r36">[36]</xref><xref ref-type="bibr" rid="article-20210.r37">[37]</xref>&#x000a0;This ciliary malfunction leads to the overproduction of epidermal growth factors, epithelial cell proliferation, increased fluid secretion, tubular ectasia, and renal cyst formation.<xref ref-type="bibr" rid="article-20210.r35">[35]</xref><xref ref-type="bibr" rid="article-20210.r36">[36]</xref><xref ref-type="bibr" rid="article-20210.r37">[37]</xref><xref ref-type="bibr" rid="article-20210.r38">[38]</xref></p>
        <p>For instance, ADPKD develops due to mutations in the genes <italic toggle="yes">PKD1</italic> and <italic toggle="yes">PKD2</italic>. These mutations cause abnormal tubular ciliary activity, dysregulation of tubular epithelial adhesion, cell differentiation, and ion channel dysfunction, which causes active fluid secretion into cysts.<xref ref-type="bibr" rid="article-20210.r35">[35]</xref><xref ref-type="bibr" rid="article-20210.r36">[36]</xref><xref ref-type="bibr" rid="article-20210.r37">[37]</xref><xref ref-type="bibr" rid="article-20210.r39">[39]</xref>&#x000a0;Renal cysts in ADPKD can hemorrhage and cause hematuria or become infected. Patients are at higher than average risk of pyelonephritis, and 25% will develop nephrolithiasis. Estrogen levels play a role in hepatic cyst development, leading to a higher prevalence of liver cysts in women compared to men. Multiple pregnancies or other estrogen exposure can further increase this likelihood. Many hepatic cysts are common, but liver failure is rare.&#x000a0;Vascular sclerosis and interstitial fibrosis may also develop.&#x000a0;Failure of normal ductal plate remodeling causes the persistence of embryologic bile ducts, which become dilated and form hepatic cysts.</p>
        <p>ARPKD is due to mutations in the <italic toggle="yes">PKHD1</italic> gene and presents in childhood. Severe cases result in perinatal death, most often due to pulmonary hypoplasia, and patients who survive until adulthood have some degree of liver fibrosis. Imaging shows small cystic lesions due to renal tubular dilation rather than the large non-communicating cysts seen in ADPKD.<xref ref-type="bibr" rid="article-20210.r6">[6]</xref><xref ref-type="bibr" rid="article-20210.r15">[15]</xref></p>
        <p>Autosomal dominant tubulointerstitial kidney disease is also characterized by progressive interstitial fibrosis and tubular damage due to ciliary dysfunction. Patients usually present with ESRD within 10 years of when their affected parent had ESRD. At least 6 separate genes are known to be involved, and the most common are <italic toggle="yes">UMOD</italic>, <italic toggle="yes">MUC1</italic>, and <italic toggle="yes">REN</italic>.&#x000a0;Other physiologic abnormalities, including polydipsia and polyuria, may also result.<xref ref-type="bibr" rid="article-20210.r33">[33]</xref><xref ref-type="bibr" rid="article-20210.r40">[40]</xref></p>
        <p>Nephronophthisis is an autosomal recessive genetic disorder caused by mutations in the <italic toggle="yes">NPH</italic> gene. There are 26 known mutations, and many more are unidentified.&#x000a0;</p>
        <p>Simple cysts are thin-walled sacs filled with serous fluid lined with cuboidal or flattened epithelial cells. It is thought their genesis is a hypertrophic response to ischemia or obstruction. They project outside the renal parenchyma into the pelvic area and are called parapelvic renal cysts.<xref ref-type="bibr" rid="article-20210.r15">[15]</xref></p>
        <p>Hypertension related to RCD can be a prominent feature from as young as the neonatal period. It results from the cystic distortion of the intrarenal architecture, which causes activation of the renin-angiotensin-aldosterone system and increased sympathetic nervous system activation.<xref ref-type="bibr" rid="article-20210.r41">[41]</xref><xref ref-type="bibr" rid="article-20210.r42">[42]</xref>&#x000a0;The polyuria caused by renal tubule concentrating defects can also activate the V1 vasopressin receptors, causing vasoconstriction. It is also thought that the polycystin proteins (which are deficient in PKD) help decrease vascular tone.<xref ref-type="bibr" rid="article-20210.r41">[41]</xref></p>
      </sec>
      <sec id="article-20210.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The primary histological abnormalities in RCD are cystic dilatations within the nephron's various components, including the glomerulus, tubule, and collecting ducts. On microscopic examination, the cystic dilatation of these structures can be&#x000a0;2 to 3 times larger than normal size.<xref ref-type="bibr" rid="article-20210.r5">[5]</xref><xref ref-type="bibr" rid="article-20210.r43">[43]</xref></p>
      </sec>
      <sec id="article-20210.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Often, RCD is suspected due to clinical features but must be confirmed with diagnostic studies. Clinical findings, for the most part, are nonspecific and, when present, vary based on the underlying etiology and may range from asymptomatic to ESRD. However, a few conditions may be somewhat differentiated by extrarenal symptoms that are associated with them. Additionally, obtaining a comprehensive family history can significantly inform the diagnosis. The following are the clinical features of some common CKD etiologies.<xref ref-type="bibr" rid="article-20210.r5">[5]</xref>&#x000a0;</p>
        <p><bold>Autosomal-dominant polycystic kidney disease:</bold> Patients typically do not show symptoms until they are aged 30&#x000a0;to 50; however, children with ADPK have higher rates of proteinuria and hypertension than children without ADPKD.<xref ref-type="bibr" rid="article-20210.r6">[6]</xref> Clinical presentation in adults typically includes flank pain, intermittent hematuria, cyst hemorrhage, hypertension, and chronic renal failure. Furthermore, up to 25% of ADPKD patients will develop kidney stones. Chronic flank or back pain is frequently noted secondary to comorbid conditions and complications, including the following: cyst rupture, infection, or hemorrhage; kidney enlargement; urolithiasis; or urinary tract infection.<xref ref-type="bibr" rid="article-20210.r6">[6]</xref><xref ref-type="bibr" rid="article-20210.r44">[44]</xref>&#x000a0;Additionally, ADPKD&#x000a0;commonly has several extrarenal clinical features. Hepatic cysts are the most common, followed by hepatomegaly, pancreatic cysts, diverticulosis, valvular cardiac disease, cerebral aneurysms, and seminal vesicle cysts.&#x000a0;Clinical features can be similar to other RCDs. Therefore, a positive family history can assist in diagnosis, as 75% to 90% of these patients have a parent who shares the same diagnosis.<xref ref-type="bibr" rid="article-20210.r45">[45]</xref></p>
        <p><bold>Autosomal recessive polycystic kidney disease:</bold>&#x000a0;Clinical features typically appear antenatally and in newborns but may also present in early adulthood. Patients have concurrent liver disease with developmental biliary defects resulting in dilated bile ducts, sometimes with cyst formation. Clinical expression of hepatic disease is variable, with the most common complications being portal hypertension, hypersplenism, esophageal varices, and cholangitis. One estimate of long-term survivors is that 7% of patients will need liver transplantation due to portal hypertension or recurrent cholangitis.<xref ref-type="bibr" rid="article-20210.r15">[15]</xref><xref ref-type="bibr" rid="article-20210.r46">[46]</xref>&#x000a0;In two-thirds of affected newborns, significant hypertension develops within the first few months after birth. Due to the early onset of the disease, perinatal clinical features are commonly seen, including oligohydramnios or anhydramnios; low Apgar scores; Potter facies with limb defects; stomach compression and feeding difficulty secondary to enlarged kidneys; and pulmonary hypoplasia with respiratory distress (a common cause of mortality).<xref ref-type="bibr" rid="article-20210.r47">[47]</xref><xref ref-type="bibr" rid="article-20210.r48">[48]</xref><xref ref-type="bibr" rid="article-20210.r49">[49]</xref>&#x000a0;Other clinical manifestations may include left ventricular hypertrophy, neurocognitive impairment, polyuria, polydipsia, recurrent urinary tract infections, and ESRD.<xref ref-type="bibr" rid="article-20210.r5">[5]</xref><xref ref-type="bibr" rid="article-20210.r50">[50]</xref><xref ref-type="bibr" rid="article-20210.r51">[51]</xref></p>
        <p><bold>Autosomal-dominant tubulointerstitial kidney disease:</bold>&#x000a0;Clinical presentation depends on the specific gene mutation, but polydipsia and polyuria are common. Blood pressure is usually normal, and renal failure progresses slowly with a median age of 45 for ESRD. The most common gene abnormality occurs with the&#x000a0;<italic toggle="yes">UMOD gene&#x000a0;</italic>and&#x000a0;is associated with hyperuricemia and gout.<xref ref-type="bibr" rid="article-20210.r13">[13]</xref><xref ref-type="bibr" rid="article-20210.r15">[15]</xref></p>
        <p><bold>Nephronophthisis:</bold>&#x000a0;This condition is characterized by symptoms of ESRD by the age of 30 years with normal blood pressure. Extrarenal lesions present in 10% to 20% of patients, including retinitis pigmentosa, cerebellar vermis hypoplasia, gaze palsy, and hepatic fibrosis. JNPHP presents with growth retardation, polyuria and polydipsia, skeletal dysplasia, anemia, and progressive renal failure.<xref ref-type="bibr" rid="article-20210.r15">[15]</xref></p>
        <p><bold>Tuberous sclerosis:</bold>&#x000a0;This condition is due to mutations in the genes <italic toggle="yes">TSC1</italic> and <italic toggle="yes">TSC2,</italic> which result in hamartoma formation throughout the body. Patients can present with several characteristic findings, including angiofibroma, facial nevi, cardiac rhabdomyoma, epilepsy, and mental retardation. Renal findings include angiomyolipomas, renal cysts, and renal cell carcinomas. One study showed that about 71% of patients had renal lesions; the most common was angiomyolipomas (61%), and 28% had renal cysts.<xref ref-type="bibr" rid="article-20210.r15">[15]</xref><xref ref-type="bibr" rid="article-20210.r52">[52]</xref></p>
        <p><bold>Von Hippel-Lindau syndrome:</bold>&#x000a0;This syndrome is caused by defects in the <italic toggle="yes">VHL</italic> gene, which produces a tumor suppressor. In addition to cystic disease of the kidneys, which is typically asymptomatic, characteristic cystic lesions can be present in other organs, such as the pancreas and epidermis. The diagnosis of this condition varies based on family history. In patients with a positive family history of this condition, the presence of a von Hippel-Lindau&#x02013;associated lesion&#x02014;retinal angiomas, spinal or cerebellar hemangioblastomas, endolymphatic sac tumors, renal cell carcinoma, pheochromocytoma, pancreatic cysts, neuroendocrine tumors, or epididymal cystadenomas&#x02014;meets the criteria for clinical diagnosis. In patients without a family history, clinical diagnosis is confirmed by the presence of either (1) 2&#x000a0;hemangioblastomas or retinal angiomas or (2) at least 1 hemangioblastoma or retinal angioma, in addition to at least 1 other von Hippel-Lindau&#x02013;associated lesion.&#x000a0;A positive result for a <italic toggle="yes">VHL</italic> gene mutation is also diagnostic if the family history is negative.<xref ref-type="bibr" rid="article-20210.r15">[15]</xref><xref ref-type="bibr" rid="article-20210.r53">[53]</xref><xref ref-type="bibr" rid="article-20210.r54">[54]</xref></p>
        <p><bold>Acquired renal cystic disease:</bold>&#x000a0;In patients on dialysis, this condition usually progresses without symptoms; however, it can present with a palpable renal mass, gross hematuria, flank pain, urinary tract infection, or renal colic.<xref ref-type="bibr" rid="article-20210.r55">[55]</xref><xref ref-type="bibr" rid="article-20210.r56">[56]</xref></p>
        <p><bold>Multicystic dysplastic kidney:</bold>&#x000a0;Most commonly, patients with this condition are identified during antenatal fetal ultrasound imaging. Patients with bilateral kidney involvement may have clinical findings of oliguria and amenorrhea. Genital tract anomalies, eg, Mayer-Rokitansky, are also common. Children with this condition are more likely to have ureteral reflex and UTIs. In most children with this condition, the cysts will spontaneously regress and have no residual symptoms.<xref ref-type="bibr" rid="article-20210.r3">[3]</xref><xref ref-type="bibr" rid="article-20210.r15">[15]</xref><xref ref-type="bibr" rid="article-20210.r57">[57]</xref></p>
        <p><bold>Simple renal cysts:</bold>&#x000a0;Patients are typically asymptomatic with no family history of kidney dysfunction. They can cause pain, hematuria, or infection, especially if the cysts are large.<xref ref-type="bibr" rid="article-20210.r3">[3]</xref><xref ref-type="bibr" rid="article-20210.r15">[15]</xref><xref ref-type="bibr" rid="article-20210.r3">[3]</xref></p>
      </sec>
      <sec id="article-20210.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>In patients presenting with nonspecific clinical features of RCD and unknown or negative family history, clinicians should perform diagnostic studies to assist in determining an accurate diagnosis. Generally, imaging studies are the primary diagnostic tool used to characterize cystic kidneys; genetic testing may be considered to assess other potential inherited etiologies. Additional laboratory studies may be used to monitor for complications and exclude differential diagnoses.<xref ref-type="bibr" rid="article-20210.r15">[15]</xref></p>
        <p>
<bold>Diagnostic Imaging Studies</bold>
</p>
        <p>Ultrasound of the kidneys is the preferred modality to evaluate RCD. Indications for ultrasound imaging include individuals with clinical symptoms of RCD (eg, flank pain, significant hypertension, or recurrent UTI), renal cysts incidentally identified on prenatal ultrasounds, or with a family history of polycystic kidney disease who are at least aged 18 years.&#x000a0;In patients with a positive family history, ultrasound imaging is used as a screening modality to diagnose RCD.<xref ref-type="bibr" rid="article-20210.r58">[58]</xref>&#x000a0;Ultrasound is often also used to monitor disease progression. Characteristic diagnostic findings for RCD on kidney ultrasound depend on the etiology, including the following:</p>
        <p>
<bold>Autosomal-dominant polycystic kidney disease</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Enlarged echogenic kidneys, often with a "lumpy" contour</p>
          </list-item>
          <list-item>
            <p>Multiple, large, bilateral renal cysts; the following is generally used for diagnosis:
<list list-type="bullet"><list-item><p>Age 15 to 39 years: &#x02265;3 cysts in one or both kidneys</p></list-item><list-item><p>Age 40 to 59 years: &#x02265;2 cysts in both kidneys</p></list-item><list-item><p>Age &#x0003e;60 years:&#x000a0;&#x02265;4 cysts in both kidneys&#x000a0;<xref ref-type="bibr" rid="article-20210.r59">[59]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Cyst number and size increase with patient age&#x000a0;<xref ref-type="bibr" rid="article-20210.r6">[6]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Autosomal recessive polycystic kidney disease</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Enlarged kidneys, normal contour, echogenic with poor cortico-medullary junction differentiation</p>
          </list-item>
          <list-item>
            <p>Dilated collecting ducts</p>
          </list-item>
          <list-item>
            <p>Multiple small bilateral cysts, 5 to 7 mm on average</p>
          </list-item>
          <list-item>
            <p>Compression of the renal cortex with hypoechoic halos</p>
          </list-item>
          <list-item>
            <p>No evidence of renal cysts in parents of infants with&#x000a0;RCD&#x000a0;<xref ref-type="bibr" rid="article-20210.r3">[3]</xref></p>
          </list-item>
        </list>
        <p>
<bold>&#x000a0;Nephronophthisis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hyperechoic normal or small kidneys with normal to small-sized cysts; in the infantile variant, kidneys are enlarged&#x000a0;<xref ref-type="bibr" rid="article-20210.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Renal cysts primarily within the corticomedullary junction&#x000a0;<xref ref-type="bibr" rid="article-20210.r6">[6]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Autosomal-dominant tubulointerstitial kidney disease</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Bilateral atrophic or normal-sized kidneys with microcysts</p>
          </list-item>
          <list-item>
            <p>Antenatal fetal anatomy ultrasound may show associated fetal anomalies (eg,&#x000a0;cleft palate, spina bifida, and polydactyly)&#x000a0;<xref ref-type="bibr" rid="article-20210.r15">[15]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Medullary cystic kidney disease</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Unconnected multiple cysts of various sizes&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Decreased amount of renal parenchyma</p>
          </list-item>
          <list-item>
            <p>Usually unilateral, but occasionally bilateral</p>
          </list-item>
          <list-item>
            <p>Genital anomalies may also be visualized&#x000a0;<xref ref-type="bibr" rid="article-20210.r60">[60]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Acquired renal cystic disease</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Bilateral small cysts primarily in the cortical area of the kidney</p>
          </list-item>
          <list-item>
            <p>Small or atrophic kidneys&#x000a0;<xref ref-type="bibr" rid="article-20210.r59">[59]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Simple renal cysts</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Sharply-defined cysts with thin, smooth walls without internal debris or cystic communication</p>
          </list-item>
          <list-item>
            <p>Normal-sized kidneys</p>
          </list-item>
          <list-item>
            <p>Typically unilateral&#x000a0;<xref ref-type="bibr" rid="article-20210.r5">[5]</xref><xref ref-type="bibr" rid="article-20210.r15">[15]</xref></p>
          </list-item>
        </list>
        <p>Renal CT and MRI may be used to evaluate RCD further, particularly if findings are nonspecific on ultrasound imaging.<xref ref-type="bibr" rid="article-20210.r60">[60]</xref>&#x000a0;These modalities can better visualize cyst properties or disease progression for some conditions, such as tuberous sclerosis and simple and complex renal cysts.<xref ref-type="bibr" rid="article-20210.r5">[5]</xref>&#x000a0;Additionally, the liver and spleen should be imaged with CT or MRI if initial ultrasound imaging is inadequate to evaluate associated extrarenal pathologies (eg, biliary duct enlargement, esophageal varices, and hepatosplenomegaly).<xref ref-type="bibr" rid="article-20210.r3">[3]</xref><xref ref-type="bibr" rid="article-20210.r61">[61]</xref></p>
        <p>The Bosniak classification may be used in interpreting findings on CT imaging, with and without contrast, by classifying cystic lesions.<xref ref-type="bibr" rid="article-20210.r62">[62]</xref>&#x000a0;Cyst characteristics are categorized into 5 different groups according to their malignant potential. This classification aids clinicians in determining the best management approach with the following recommendations for each respective category.<xref ref-type="bibr" rid="article-20210.r5">[5]</xref><xref ref-type="bibr" rid="article-20210.r56">[56]</xref><xref ref-type="bibr" rid="article-20210.r63">[63]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Class I: A benign simple cyst with a thin wall without septa, calcifications, or solid components. Further evaluation is not required. Malignant potential is estimated at &#x0003c; 1%.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Class II: There are two categories: (1) A benign simple cyst with a few thin walls and septa with fine calcifications but no enhancement. (2) Homogenous high-attenuating masses&#x000a0;&#x02264;3 cm that have sharp margins and do not enhance. Follow-up is usually unnecessary but may be suggested 6 or 12 months later in selected patients to confirm the diagnosis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Class IIF: An indeterminate cyst designation between categories II and III with two types: (1) Cysts with multiple thin septa with smooth, minimally thickened walls that may have nodular calcification. There may be the impression of some mild enhancement. (2) High attenuation masses &#x0003e;3cm but with no enhancement. The estimated malignant potential is 5%. Follow-up imaging with CT or ultrasound is recommended, usually at 6 months and then annually for 5 years.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Class III: The cysts demonstrate a multilocular lesion with thickened walls or septa, irregular calcifications, or measurable vascular enhancement &#x0003e;10 Hounsfield units. Close follow-up or surgical excision with partial or total nephrectomy is recommended. These cysts have an estimated malignancy rate of 55%.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Class IV: These cysts are typically large nodular lesions with enhancing solid or necrotic components.&#x000a0;These cysts have an extremely high malignant potential of almost 100%. Partial or total nephrectomy surgery is recommended.&#x000a0;</p>
          </list-item>
        </list>
        <p>Diagnostic imaging is also recommended for some etiologies to monitor RCD progression and extrarenal manifestations. For instance, annual abdominal ultrasound examinations are recommended in patients diagnosed with ARPKD to identify early portal hypertension and to monitor kidney size in infants with severe or rapidly progressive disease.<xref ref-type="bibr" rid="article-20210.r64">[64]</xref>&#x000a0;Individuals diagnosed with ADPKD&#x000a0;who work&#x000a0;in high-risk occupations (eg, airline pilots), are scheduled to have major surgery, experience central nervous system symptoms (eg, new-onset severe headache or loss of consciousness), or have a family history of intracranial aneurysms should have imaging studies to screen for intracranial aneurysm.<xref ref-type="bibr" rid="article-20210.r58">[58]</xref></p>
        <p>
<bold>Genetic Testing</bold>
</p>
        <p>Genetic testing for known mutations may be considered to help establish a diagnosis in patients with suspected hereditary etiologies of RCD. However, clinicians should understand that genetic testing is not definitive, as current testing may not identify newer mutations. For instance, though there are 26 known genetic mutations of the&#x000a0;<italic toggle="yes">NPHP</italic>&#x000a0;genes that cause&#x000a0;nephronophthisis, recent genetic analysis only&#x000a0;detects 9 to 12 mutations.<xref ref-type="bibr" rid="article-20210.r3">[3]</xref></p>
        <p>Prenatal genetic testing is recommended for pregnancies where clinicians have identified fetuses with RCD. Indications for which clinicians should offer prenatal genetic testing include fetuses with 1 or more unilateral cysts if there are extrarenal manifestations present, fetuses with bilateral CKD or enlarged kidneys regardless of oligohydramnios or extrarenal malformations, or if ADPKD or ARPKD are suspected.<xref ref-type="bibr" rid="article-20210.r3">[3]</xref></p>
        <p>
<bold>Laboratory Studies</bold>
</p>
        <p>Laboratory studies are performed to assess kidney function or identify extra renal manifestations of RCD, such as liver disease. In patients with ADPKD, albuminuria, proteinuria, and a decreased glomerular filtration rate (GFR) are frequently identified.<xref ref-type="bibr" rid="article-20210.r3">[3]</xref>&#x000a0;Furthermore, urinary&#x000a0;cultures are often positive for&#x000a0;<italic toggle="yes">Escherichia coli</italic>, <italic toggle="yes">Staphylococcus aureus</italic>,&#x000a0;<italic toggle="yes">Enterococcus</italic>,&#x000a0;<italic toggle="yes">Lactobacillus</italic>, or anaerobic bacteria.&#x000a0;However, negative urine culture results are possible when infected renal cysts are not in contact with the urinary space.<xref ref-type="bibr" rid="article-20210.r58">[58]</xref></p>
        <p>Characteristic findings of ARPKD in laboratory studies include hyponatremia and dilute urine osmolality.<xref ref-type="bibr" rid="article-20210.r5">[5]</xref> Also, clinicians may perform bilirubin, hepatic enzyme, and complete blood cell counts to help identify associated portal hypertension and splenic dysfunction.&#x000a0;Thrombocytopenia due to splenic activity and portal hypertension can also be observed.<xref ref-type="bibr" rid="article-20210.r65">[65]</xref></p>
        <p>Depending on the genetic mutation, ADTKD can present with hyperuricemia, hyperkalemia, anemia, acidosis, elevated liver enzymes, neutropenia, or hypogammaglobulinemia. Nephronophthisis can show hyponatremia due to impaired sodium reabsorption.<xref ref-type="bibr" rid="article-20210.r15">[15]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-20210.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The management of RCDs is primarily supportive with treatment and monitoring of any sequelae, eg, hypertension, infection, and pain. Hypertension is an almost universal finding in polycystic kidney disease, and several options exist to control high blood pressure. Preferred agents include angiotensin receptor blockers and angiotensin-converting enzyme inhibitors.<xref ref-type="bibr" rid="article-20210.r41">[41]</xref> Calcium channel blockers may also maintain a blood pressure of &#x0003c;130/80 mm Hg. About two-thirds of hypertensive patients will require more than 1 agent; however, optimal management of hypertension may slow the decline in renal function with this disease.<xref ref-type="bibr" rid="article-20210.r66">[66]</xref>&#x000a0;The following are other management recommendations that are targeted to the underlying etiologies.</p>
        <p>
<bold>Autosomal Dominant Polycystic Kidney Disease </bold>
</p>
        <p>In ADPKD, recommendations include drinking at least 2 to 3 liters of water daily to naturally suppress vasopressin, which can help reduce cyst formation and growth.<xref ref-type="bibr" rid="article-20210.r67">[67]</xref><xref ref-type="bibr" rid="article-20210.r68">[68]</xref><xref ref-type="bibr" rid="article-20210.r69">[69]</xref>&#x000a0;Additional measures include restricting sodium to&#x000a0;&#x02264;2 g of salt daily, regularly exercising, maintaining a normal weight, and managing hypertension.<xref ref-type="bibr" rid="article-20210.r67">[67]</xref><xref ref-type="bibr" rid="article-20210.r70">[70]</xref><xref ref-type="bibr" rid="article-20210.r71">[71]</xref></p>
        <p>Tolvaptan is a vasopressin receptor antagonist at the V2 receptor that is&#x000a0;effective for ADPKD and has been shown to slow the growth and development of renal cysts.<xref ref-type="bibr" rid="article-20210.r72">[72]</xref><xref ref-type="bibr" rid="article-20210.r73">[73]</xref><xref ref-type="bibr" rid="article-20210.r74">[74]</xref><xref ref-type="bibr" rid="article-20210.r75">[75]</xref>&#x000a0;Tolvaptan&#x000a0;blocks vasopressin signaling, which would otherwise increase intracellular cyclic adenosine monophosphate that stimulates the growth and proliferation of renal cysts; it&#x000a0;is the only US Food and Drug Administration (FDA)-approved medication for ADPKD.<xref ref-type="bibr" rid="article-20210.r72">[72]</xref><xref ref-type="bibr" rid="article-20210.r76">[76]</xref>&#x000a0;However, tolvaptan&#x000a0;appears to be most useful in younger patients with ADPKD and early or rapidly progressive renal disease; it is less effective in patients older than 55.<xref ref-type="bibr" rid="article-20210.r75">[75]</xref><xref ref-type="bibr" rid="article-20210.r77">[77]</xref>&#x000a0;</p>
        <p>Clinicians should be aware that tolvaptan is a potentially dangerous drug that can cause significant liver damage or even acute liver failure requiring transplantation. Renal function tests should be monitored regularly. A recommended surveillance schedule is before therapy, 2 and 4 weeks after starting treatment, followed by every month for 18 months, and then quarterly. Elevated liver enzymes are most likely to occur during the first 18 months of use but will generally resolve after treatment discontinuation.<xref ref-type="bibr" rid="article-20210.r77">[77]</xref>&#x000a0;The drug also causes significant diuresis with polyuria and severe thirst. Adverse effects result in drug discontinuation in about 8% of patients.</p>
        <p>Cyst infections can develop in ADPKD, which can be treated with a course of antibiotics that penetrate cysts well, such as ciprofloxacin, clindamycin, sulfamethoxazole-trimethoprim, erythromycin, chloramphenicol, or tetracycline. For chronic pain, which frequently occurs in patients with ADPKD, alternative pain management strategies (eg, antidepressants and avoidance of activities that can trigger pain) and referral to a pain management specialist should be considered. Nonsteroidal anti-inflammatory drugs (NSAIDs) should be avoided due to the risk of toxicity.<xref ref-type="bibr" rid="article-20210.r58">[58]</xref></p>
        <p>
<bold>Autosomal Recessive Polycystic Kidney Disease</bold>
</p>
        <p>ARPKD has no curative treatment other than transplantation; therefore, there is only&#x000a0;symptomatic management, including supportive respiratory therapy for pulmonary insufficiency, dialysis or kidney transplantation for end-stage renal failure, salt restriction, antihypertensives for hypertension, and loop diuretics for edema.<xref ref-type="bibr" rid="article-20210.r78">[78]</xref>&#x000a0;The associated hepatobiliary disease may require the administration of synthetic bile acids, portosystemic vascular shunting, or a liver transplant. Several ongoing trials are evaluating its usefulness in pediatric ARPKD.<xref ref-type="bibr" rid="article-20210.r79">[79]</xref>&#x000a0;Adverse effects and cost limit its use. Tolvaptan is the only drug specifically FDA-approved for ADPKD, but the repurposing of other medications that might be effective in polycystic kidney disease is being investigated.<xref ref-type="bibr" rid="article-20210.r74">[74]</xref></p>
        <p>
<bold>Tuberous Sclerosis Syndrome</bold>
</p>
        <p>Patients with tuberous sclerosis-associated RCD should be monitored for&#x000a0;angiomyolipoma lesions that often develop. The 2012 International Tuberous Sclerosis Consensus Group recommends initiating first-line treatment with mTOR inhibitor therapy for asymptomatic lesions &#x0003e;3 cm. Another study showed evidence that the drug&#x000a0;everolimus effectively reduced the volume of angiomyolipoma lesions.<xref ref-type="bibr" rid="article-20210.r5">[5]</xref>&#x000a0;Embolization is necessary for angiomyolipoma lesions that lead to acute hemorrhage; for asymptomatic lesions &#x0003e;3 cm, embolization or nephron-sparing resection may also be considered.<xref ref-type="bibr" rid="article-20210.r5">[5]</xref></p>
        <p>
<bold>Von Hippel-Lindau Syndrome</bold>
</p>
        <p>Treatment of RCD associated with this condition is based on the management recommendations specified in the Bosniak classification. Follow-up and imaging at 3, 6, and 12 months after diagnosis, and then yearly, is recommended for patients in the IIF class. Patients in class III&#x000a0;should have close follow-up and possibly surgical excision due to the risk of malignancy; those in class IV&#x000a0;should have renal cysts surgically excised.<xref ref-type="bibr" rid="article-20210.r5">[5]</xref><xref ref-type="bibr" rid="article-20210.r15">[15]</xref></p>
        <p>
<bold>Nephronophthisis and Autosomal-Dominant Tubulointerstitial Kidney Disease</bold>
</p>
        <p>Nephronophthisis and ADTKD are managed supportively to treat sequelae symptoms; currently, there are no pharmacologic treatments. Salt supplementation should be used when there is severe salt wasting. In addition, diuretics, sodium restriction, NSAIDs, and renin-angiotensin-suppressing medications should be avoided. In patients with ESRD, dialysis and kidney transplantation should be considered. Allopurinol or&#x000a0;febuxostat are used to treat the hyperuricemia associated with ADTKD.<xref ref-type="bibr" rid="article-20210.r15">[15]</xref></p>
        <p>
<bold>Acquired Cystic Renal Disease</bold>
</p>
        <p>Patients with this condition are at significantly increased risk of hemorrhage and renal cell carcinoma, so initial and periodic screening is recommended in dialysis patients. Although transplant diminishes the size of the cysts, it does not eliminate the risk of renal cell carcinoma, and transplanted patients should also have a yearly ultrasound of the native kidney as part of follow-up.<xref ref-type="bibr" rid="article-20210.r80">[80]</xref></p>
        <p>
<bold>Simple Renal Cysts</bold>
</p>
        <p>Cysts that are Bosniak classes I&#x000a0;and&#x000a0;II generally do not require follow-up. Renal cysts generally produce no symptoms, but if they become symptomatic, needle aspiration, sclerotherapy, or cyst unroofing may be needed. Laparoscopic techniques can be performed for complex cysts.<xref ref-type="bibr" rid="article-20210.r81">[81]</xref>&#x000a0;Surgical excision should be considered for patients in class III&#x000a0;and is recommended for those in Bosniak class IV.<xref ref-type="bibr" rid="article-20210.r5">[5]</xref></p>
        <p>
<bold>Investigational Therapies</bold>
</p>
        <p>Targeted therapies for genetic renal cystic diseases are being actively investigated, and several are undergoing extensive clinical trials.<xref ref-type="bibr" rid="article-20210.r82">[82]</xref><xref ref-type="bibr" rid="article-20210.r83">[83]</xref>&#x000a0;More investigation is required before these agents can be recommended for clinical use.</p>
        <list list-type="bullet">
          <list-item>
            <p>Various drugs such as methylprednisone, urinary alkalinization, lovastatin, epidermal growth factor tyrosine kinase receptor inhibitors, paclitaxel, bardoxolone methyl, peroxisome proliferator-activated receptor agonists, mitogen-activated protein kinase inhibitors, and cyclin-dependent kinase inhibitors are undergoing animal studies to assess clinical utility.<xref ref-type="bibr" rid="article-20210.r45">[45]</xref><xref ref-type="bibr" rid="article-20210.r47">[47]</xref><xref ref-type="bibr" rid="article-20210.r48">[48]</xref><xref ref-type="bibr" rid="article-20210.r82">[82]</xref><xref ref-type="bibr" rid="article-20210.r84">[84]</xref><xref ref-type="bibr" rid="article-20210.r85">[85]</xref><xref ref-type="bibr" rid="article-20210.r86">[86]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Drugs targeting mTOR signaling pathways,&#x000a0;such as rapamycin, by checking cellular proliferation, are under phase&#x000a0;2 and&#x000a0;3 clinical trials.<xref ref-type="bibr" rid="article-20210.r82">[82]</xref><xref ref-type="bibr" rid="article-20210.r87">[87]</xref><xref ref-type="bibr" rid="article-20210.r88">[88]</xref><xref ref-type="bibr" rid="article-20210.r89">[89]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Statins have shown some benefits in lowering serum lipid levels in ADPKD patients, reducing proteinuria, and slowing the decline in GFR, but their effect on disease progression is still uncertain.<xref ref-type="bibr" rid="article-20210.r90">[90]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Combined somatostatin and tolvaptan block the effect of cyclic adenosine monophosphate and inhibit fluid secretion and cell proliferation.<xref ref-type="bibr" rid="article-20210.r82">[82]</xref><xref ref-type="bibr" rid="article-20210.r91">[91]</xref><xref ref-type="bibr" rid="article-20210.r92">[92]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Triptolide, which affects calcium signaling, also exhibits antiproliferative effects in ADPKD.<xref ref-type="bibr" rid="article-20210.r93">[93]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Salsalate, an NSAID, and metformin, either together or separately, may help slow the progression of ADPKD.<xref ref-type="bibr" rid="article-20210.r94">[94]</xref><xref ref-type="bibr" rid="article-20210.r95">[95]</xref><xref ref-type="bibr" rid="article-20210.r96">[96]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Amiloride and caffeine restriction have shown some benefits in limiting cyst growth in animals but have not demonstrated similar efficacy in humans.<xref ref-type="bibr" rid="article-20210.r97">[97]</xref><xref ref-type="bibr" rid="article-20210.r98">[98]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Bosutinib, an oral tyrosine kinase inhibitor, was studied for possible use in ADPKD.&#x000a0;Bosutinib&#x000a0;reduced the renal growth rate but did not affect the decline in GFR.<xref ref-type="bibr" rid="article-20210.r99">[99]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20210.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Excluding differential diagnoses is essential to arrive at the most accurate diagnosis. Accurate diagnosis enables clinicians to employ the most suitable, currently available, and targeted treatment strategies.&#x000a0;A complete history and physical examination for secondary findings, imaging modalities, and genetic testing can help differentiate the various etiologies of renal cysts. Some conditions that can appear as RCDs include angiomyolipomas, cystic renal neoplasms, extrarenal pelvis, hemangiomas, hydronephrosis, nephrolithiasis, neuroblastoma, parapelvic renal cysts, renal abscess, renal dysplasia, lipomas, and many rare genetic disorders.<xref ref-type="bibr" rid="article-20210.r6">[6]</xref><xref ref-type="bibr" rid="article-20210.r15">[15]</xref></p>
      </sec>
      <sec id="article-20210.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Generally, the prognosis in cystic renal disease depends on the rate of declining renal function and extrarenal manifestations. Patients who progress to ESRD at a younger age typically have a poorer prognosis.&#x000a0;</p>
        <p>For instance, ADPKD will typically progress to some degree of renal insufficiency in patients aged &#x0003e; 30 years. Ultimately, 35% to 45% of patients with ADPKD will develop end-stage renal failure by the age of 60 years, 50% by the age of 70 years, and up to 75% by the age of 75 years.&#x000a0;The GFR in ADPKD declines by about 5 mL/min/year in patients older than 40.&#x000a0;The most reliable predictor of disease progression to end-stage renal failure appears to be kidney and cyst volume measurements, particularly a total renal volume of &#x0003e; 1500 mL.<xref ref-type="bibr" rid="article-20210.r100">[100]</xref>&#x000a0;The faster the total renal volume increases, the more rapidly renal function decreases. Other predictors of a more rapid progression and poorer prognosis include the following: <xref ref-type="bibr" rid="article-20210.r101">[101]</xref><xref ref-type="bibr" rid="article-20210.r102">[102]</xref><xref ref-type="bibr" rid="article-20210.r103">[103]</xref><xref ref-type="bibr" rid="article-20210.r104">[104]</xref><xref ref-type="bibr" rid="article-20210.r105">[105]</xref><xref ref-type="bibr" rid="article-20210.r106">[106]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Black ethnicity or genetic heritage</p>
          </list-item>
          <list-item>
            <p>Diagnosis at an earlier age</p>
          </list-item>
          <list-item>
            <p>Diabetes</p>
          </list-item>
          <list-item>
            <p>Gross hematuria</p>
          </list-item>
          <list-item>
            <p>Hypertension</p>
          </list-item>
          <list-item>
            <p>Larger kidney and cyst size</p>
          </list-item>
          <list-item>
            <p>Male gender</p>
          </list-item>
          <list-item>
            <p>PKD1 genotype&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Rapidly enlarging kidneys or cyst dimensions</p>
          </list-item>
          <list-item>
            <p>Sickle cell trait</p>
          </list-item>
          <list-item>
            <p>Worsening proteinuria</p>
          </list-item>
        </list>
        <p>ADPKD does not increase the incidence of developing renal cancer, but if such a malignancy were to develop, it is more likely to be bilateral than in the general population. Renal cancer rarely causes death in such cases. Mortality is most commonly due to valvular heart disease, disseminated infection, hypertensive nephropathy, renal failure, or cerebral vascular accident due to a ruptured cerebral aneurysm from the combination of cerebral aneurysms and hypertension. Hepatic cysts are common but rarely clinically significant.<xref ref-type="bibr" rid="article-20210.r58">[58]</xref></p>
        <p>In ARPKD, hypoplastic and immature lungs are the most significant neonatal clinical problems, often requiring mechanical ventilation. Portal hypertension may develop, resulting in hypersplenism and thrombocytopenia. Frequent causes of death aside from renal failure include pulmonary insufficiency and hepatobiliary disease. Liver and kidney transplantation at a younger age is associated with longer survival rates.<xref ref-type="bibr" rid="article-20210.r3">[3]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-20210.s12" sec-type="Complications">
        <title>Complications</title>
        <p>ADPKD has several complications, including hypertension, renal failure, cyst infection, severe abdominal and flank pain, and subarachnoid hemorrhage.<xref ref-type="bibr" rid="article-20210.r15">[15]</xref>&#x000a0;The most common complication of ARPKD is respiratory distress due to pulmonary hypoplasia; other complications include portal hypertension, variceal bleeding, and renal insufficiency. Nephronophthisis can&#x000a0;be present with both hepatic and other extrarenal complications (eg, hepatic fibrosis, biliary duct enlargement, growth retardation, retinitis pigmentosa, cerebellar vermis hypoplasia, gaze palsy, hepatic fibrosis, and skeletal abnormalities).<xref ref-type="bibr" rid="article-20210.r15">[15]</xref>&#x000a0;ADTKD complications depend on the gene mutation and can include hyperuricemia, gout, hyponatremia, and polyuria.<xref ref-type="bibr" rid="article-20210.r1">[1]</xref><xref ref-type="bibr" rid="article-20210.r40">[40]</xref></p>
      </sec>
      <sec id="article-20210.s13" sec-type="Consultations">
        <title>Consultations</title>
        <p>A multidisciplinary care team is required to manage patients with RCD. This involves perinatologists, neonatologists, hepatologists, nephrologists, and geneticists to organize care for the patient from the perinatal period to adulthood. Prenatal consultation with neonatologists, maternal-fetal medicine specialists, and genetic specialists is often warranted if a kidney anomaly is identified on prenatal ultrasonography. At this consultation, topics such as ultrasonographic findings, family history, prognosis factors, and the risk of recurrence should be discussed. The patient should also receive various prenatal and postnatal genetic testing options.<xref ref-type="bibr" rid="article-20210.r3">[3]</xref></p>
      </sec>
      <sec id="article-20210.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Genetic counseling is essential for genetic renal cystic diseases such as ADPKD and ARPKD.&#x000a0;Furthermore, patient education on lifestyle modification can help mitigate these complications, and suggestions include regular medical care, salt restriction, hypertension control, a healthy BMI, hydration, and regular exercise.<xref ref-type="bibr" rid="article-20210.r107">[107]</xref></p>
      </sec>
      <sec id="article-20210.s15" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Key facts&#x000a0;pertinent when managing&#x000a0;polycystic disease are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Screening family members for polycystic kidney disease has been an ongoing controversy. Genetic testing can be conclusive but requires appropriate genetic counseling, which may not be readily available. Now that tolvaptan is available and has proven to be effective in slowing the progression of the disease, considering renal ultrasonography in relatives of affected individuals seems reasonable if patients or family members desire it. However, screening asymptomatic family members without hypertension, renal failure, or proteinuria is not generally recommended.<xref ref-type="bibr" rid="article-20210.r108">[108]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cyst volume and total kidney size appear to be the best prognostic factors in tracking polycystic kidney disease progression in ADPKD. Cysts are present throughout the renal cortex and medulla.<xref ref-type="bibr" rid="article-20210.r109">[109]</xref><xref ref-type="bibr" rid="article-20210.r110">[110]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Angiotensin-converting enzyme inhibitors and blockers are preferred for managing hypertension in patients with polycystic kidney disease.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Tolvaptan is a vasopressin V2 receptor antagonist that&#x000a0;slows the development and growth of the cysts and thus is an effective treatment of ADPKD, especially if rapidly progressive.<xref ref-type="bibr" rid="article-20210.r72">[72]</xref><xref ref-type="bibr" rid="article-20210.r76">[76]</xref>&#x000a0;It can have significant adverse effects of polyuria and severe thirst but should be considered for all appropriate ADPKD patients.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>ARKD is always associated with liver fibrosis, but hepatic symptoms are variable. When severe, hepatic symptoms include portal hypertension, splenomegaly, thrombocytopenia, and esophageal varices.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Autosomal dominant tubulointerstitial disease is characterized by tubulointerstitial fibrosis and has been recently reclassified to be called ADTKD-(<italic toggle="yes">abnormal gene name</italic>). Urine sediment is bland, and renal failure is slowly progressive. Symptoms depend on the gene abnormality, and the most common mutation is in the&#x000a0;<italic toggle="yes">UMOD</italic> gene, which codes for the uromodulin protein, and is associated with hyperuricemia and gout. Cysts are not found in the renal cortex.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Multicystic dysplastic kidney disease can be diagnosed prenatally and involves renal cysts surrounded by undifferentiated renal parenchyma, along with an undeveloped renal collecting system and vasculature. It is usually unilateral but can result in urinary reflux and UTI in the unaffected kidney. It usually spontaneously regresses around age 10 years without treatment.<xref ref-type="bibr" rid="article-20210.r111">[111]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Nephronophthisis is a common cause of ESRD in those aged younger than 30 years. It is associated with impaired renal concentrating ability, polyuria, and polydipsia. The most common type is Juvenile nephronophthisis, where ESRD is reached at a median age of 13. Cysts are found primarily in the corticomedullary junction and are often attached to the cortical collecting ducts instead of dissociated.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Medullary sponge kidney presents with many measurable abnormalities, such as distal renal tubular acidosis, hypocitraturia, hypercalciuria, and proteinuria. The cysts are generally small (microcysts) in the papilla and medulla. Ultrasound will show cystic dilation in the renal papilla (giving the impression of a "sponge" on autopsy studies) and multiple calcifications. It is strongly associated with nephrolithiasis.<xref ref-type="bibr" rid="article-20210.r111">[111]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Acquired renal cystic disease is associated with ESRD and is asymptomatic but requires monitoring for the increased incidence of renal cell carcinoma. The risk of RCC is decreased with transplant but not eliminated, so transplant ultrasounds should include the native kidneys as well.&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20210.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Adult and pediatric nephrology clinicians should coordinate to ensure appropriate continuity of care for a patient with renal cystic disease who may initially present as a child but survives to become an adult.<xref ref-type="bibr" rid="article-20210.r6">[6]</xref> RCD, especially those conditions diagnosed in patients of very young age,&#x000a0;usually requires a care team with&#x000a0;varied expertise (eg, perinatologists, neonatologists, hepatologists, nephrologists, and geneticists) to coordinate care for the patient.<xref ref-type="bibr" rid="article-20210.r3">[3]</xref>&#x000a0;</p>
        <p>Lastly, all healthcare team members should support and promote general health and lifestyle measures, optimal control of blood pressure, increased fluid intake, and dietary sodium restriction. Given the long-term progression of these diseases, it is often helpful to include a multidisciplinary team of social workers, dieticians, pharmacists, and genetic counselors.</p>
      </sec>
      <sec id="article-20210.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20210&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20210">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/kidney-health/renal-cystic-disease/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=20210">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20210/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20210">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-20210.s18">
        <fig id="article-20210.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Polycystic Kidneys (ADPKD) and Liver Cysts. CT coronal view of abdomen. Contributed by Scott Dulebohn, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="apckd__and__liver__cysts" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-20210.s19">
        <fig id="article-20210.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Polycystic Kidney Contributed by Michael Lambert, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Screen__Shot__2016-08-31__at__3.30.00__PM" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-20210.s20">
        <fig id="article-20210.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Autosomal Polycystic Kidney Disease Image courtesy S Bhimji, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="polycystickidney" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-20210.s21">
        <title>References</title>
        <ref id="article-20210.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bisceglia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Galliani</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Senger</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stallone</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sessa</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Renal cystic diseases: a review.</article-title>
            <source>Adv Anat Pathol</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>26</fpage>
            <page-range>26-56</page-range>
            <pub-id pub-id-type="pmid">16462154</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wei</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xiong</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>The Relationship Between Simple Renal Cysts and Renal Function in Patients With Type 2 Diabetes.</article-title>
            <source>Front Physiol</source>
            <year>2020</year>
            <volume>11</volume>
            <fpage>616167</fpage>
            <pub-id pub-id-type="pmid">33384617</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raina</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chakraborty</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sethi</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bergmann</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and Management of Renal Cystic Disease of the Newborn: Core Curriculum 2021.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>78</volume>
            <issue>1</issue>
            <fpage>125</fpage>
            <page-range>125-141</page-range>
            <pub-id pub-id-type="pmid">33418012</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kurschat</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>RU</given-names>
              </name>
              <name>
                <surname>Franke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maintz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schermer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Benzing</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>An approach to cystic kidney diseases: the clinician's view.</article-title>
            <source>Nat Rev Nephrol</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>10</volume>
            <issue>12</issue>
            <fpage>687</fpage>
            <page-range>687-99</page-range>
            <pub-id pub-id-type="pmid">25266212</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cramer</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Guay-Woodford</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Cystic kidney disease: a primer.</article-title>
            <source>Adv Chronic Kidney Dis</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>297</fpage>
            <page-range>297-305</page-range>
            <pub-id pub-id-type="pmid">26088074</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>RU</given-names>
              </name>
              <name>
                <surname>Benzing</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Cystic Kidney Diseases From the Adult Nephrologist's Point of View.</article-title>
            <source>Front Pediatr</source>
            <year>2018</year>
            <volume>6</volume>
            <fpage>65</fpage>
            <pub-id pub-id-type="pmid">29623269</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Vrtiska</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Irazabal</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Inherited renal cystic diseases.</article-title>
            <source>Abdom Radiol (NY)</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>41</volume>
            <issue>6</issue>
            <fpage>1035</fpage>
            <page-range>1035-51</page-range>
            <pub-id pub-id-type="pmid">27167233</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shao</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Igarashi</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Role of transcription factor hepatocyte nuclear factor-1&#x003b2; in polycystic kidney disease.</article-title>
            <source>Cell Signal</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>71</volume>
            <fpage>109568</fpage>
            <pub-id pub-id-type="pmid">32068086</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hildebrandt</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Nephronophthisis-associated ciliopathies.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2007</year>
            <month>Jun</month>
            <volume>18</volume>
            <issue>6</issue>
            <fpage>1855</fpage>
            <page-range>1855-71</page-range>
            <pub-id pub-id-type="pmid">17513324</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salomon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Saunier</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Niaudet</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Nephronophthisis.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>24</volume>
            <issue>12</issue>
            <fpage>2333</fpage>
            <page-range>2333-44</page-range>
            <pub-id pub-id-type="pmid">18607645</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ozimek-Kulik</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>Nephronophthisis-Pathobiology and Molecular Pathogenesis of a Rare Kidney Genetic Disease.</article-title>
            <source>Genes (Basel)</source>
            <year>2021</year>
            <month>Nov</month>
            <day>05</day>
            <volume>12</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">34828368</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Devuyst</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Olinger</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eckardt</surname>
                <given-names>KU</given-names>
              </name>
              <name>
                <surname>Kmoch</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rampoldi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bleyer</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Autosomal dominant tubulointerstitial kidney disease.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2019</year>
            <month>Sep</month>
            <day>05</day>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>60</fpage>
            <pub-id pub-id-type="pmid">31488840</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Econimo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Schaeffer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zeni</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cortinovis</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Alberici</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rampoldi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Scolari</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Izzi</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Autosomal Dominant Tubulointerstitial Kidney Disease: An Emerging Cause of Genetic CKD.</article-title>
            <source>Kidney Int Rep</source>
            <year>2022</year>
            <month>Nov</month>
            <volume>7</volume>
            <issue>11</issue>
            <fpage>2332</fpage>
            <page-range>2332-2344</page-range>
            <pub-id pub-id-type="pmid">36531871</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalyoussef</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Prasad</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Barone</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Segmental multicystic dysplastic kidney in children.</article-title>
            <source>Urology</source>
            <year>2006</year>
            <month>Nov</month>
            <volume>68</volume>
            <issue>5</issue>
            <fpage>1121.e9</fpage>
            <page-range>1121.e9-11</page-range>
            <pub-id pub-id-type="pmid">17095057</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sekine</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hidaka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moriyama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shikida</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shimazu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ishikawa</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Uchiyama</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kataoka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kawano</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kurashige</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Suwabe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakatani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Otsuka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kai</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Katayama</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Makabe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Manabe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shimabukuro</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Nakanishi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nishio</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hattanda</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hanaoka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Miura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hoshino</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tsuchiya</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mochizuki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Horie</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Narita</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Muto</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Cystic Kidney Diseases That Require a Differential Diagnosis from Autosomal Dominant Polycystic Kidney Disease (ADPKD).</article-title>
            <source>J Clin Med</source>
            <year>2022</year>
            <month>Nov</month>
            <day>03</day>
            <volume>11</volume>
            <issue>21</issue>
            <pub-id pub-id-type="pmid">36362756</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scandling</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Acquired cystic kidney disease and renal cell cancer after transplantation: time to rethink screening?</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2007</year>
            <month>Jul</month>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>621</fpage>
            <page-range>621-2</page-range>
            <pub-id pub-id-type="pmid">17699473</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rabelo</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Oliveira</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Diniz</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Filgueiras</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Pezzuti</surname>
                <given-names>IL</given-names>
              </name>
              <name>
                <surname>Tatsuo</surname>
                <given-names>ES</given-names>
              </name>
            </person-group>
            <article-title>Natural history of multicystic kidney conservatively managed: a prospective study.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2004</year>
            <month>Oct</month>
            <volume>19</volume>
            <issue>10</issue>
            <fpage>1102</fpage>
            <page-range>1102-7</page-range>
            <pub-id pub-id-type="pmid">15258845</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Society for Maternal-Fetal Medicine (SMFM)</collab>
              <name>
                <surname>Chetty</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Multicystic dysplastic kidney.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>225</volume>
            <issue>5</issue>
            <fpage>B21</fpage>
            <page-range>B21-B22</page-range>
            <pub-id pub-id-type="pmid">34507790</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pfau</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Knauf</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Update on Nephrolithiasis: Core Curriculum 2016.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>68</volume>
            <issue>6</issue>
            <fpage>973</fpage>
            <page-range>973-985</page-range>
            <pub-id pub-id-type="pmid">27497526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Imam</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Patail</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Patail</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Medullary Sponge Kidney: Current Perspectives.</article-title>
            <source>Int J Nephrol Renovasc Dis</source>
            <year>2019</year>
            <volume>12</volume>
            <fpage>213</fpage>
            <page-range>213-218</page-range>
            <pub-id pub-id-type="pmid">31576161</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Granata</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bruschi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Candiano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Catalano</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ghiggeri</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Stallone</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zaza</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Proteomics Insights into Medullary Sponge Kidney Disease: Review of the Recent Results of an Italian Research Collaborative Network.</article-title>
            <source>Kidney Blood Press Res</source>
            <year>2022</year>
            <volume>47</volume>
            <issue>12</issue>
            <fpage>683</fpage>
            <page-range>683-692</page-range>
            <pub-id pub-id-type="pmid">36265463</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Waingankar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hayek</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Okeke</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Calyceal diverticula: a comprehensive review.</article-title>
            <source>Rev Urol</source>
            <year>2014</year>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>29</fpage>
            <page-range>29-43</page-range>
            <pub-id pub-id-type="pmid">24791153</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harris</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>VE</given-names>
              </name>
            </person-group>
            <article-title>Polycystic kidney disease.</article-title>
            <source>Annu Rev Med</source>
            <year>2009</year>
            <volume>60</volume>
            <fpage>321</fpage>
            <page-range>321-37</page-range>
            <pub-id pub-id-type="pmid">18947299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liebau</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Mekahli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Perrone</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Soyfer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fedeles</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Polycystic Kidney Disease Drug Development: A Conference Report.</article-title>
            <source>Kidney Med</source>
            <year>2023</year>
            <month>Mar</month>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>100596</fpage>
            <pub-id pub-id-type="pmid">36698747</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r25">
          <label>25</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Finnigan</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <chapter-title>Polycystic Kidney Disease In Adults (Archived)</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>11</month>
            <day>4</day>
            <pub-id pub-id-type="pmid">29261941</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chapman</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Devuyst</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Eckardt</surname>
                <given-names>KU</given-names>
              </name>
              <name>
                <surname>Gansevoort</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Horie</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kasiske</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Odland</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pei</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Perrone</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Pirson</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Schrier</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Torra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Watnick</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wheeler</surname>
                <given-names>DC</given-names>
              </name>
              <collab>Conference Participants</collab>
            </person-group>
            <article-title>Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.</article-title>
            <source>Kidney Int</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>88</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-27</page-range>
            <pub-id pub-id-type="pmid">25786098</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reed</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>McFann</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kimberling</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Pei</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Gabow</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Christopher</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Petersen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kelleher</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fain</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schrier</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Presence of de novo mutations in autosomal dominant polycystic kidney disease patients without family history.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>52</volume>
            <issue>6</issue>
            <fpage>1042</fpage>
            <page-range>1042-50</page-range>
            <pub-id pub-id-type="pmid">18640754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guay-Woodford</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Renal cystic diseases: diverse phenotypes converge on the cilium/centrosome complex.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>21</volume>
            <issue>10</issue>
            <fpage>1369</fpage>
            <page-range>1369-76</page-range>
            <pub-id pub-id-type="pmid">16823577</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saunier</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Salomon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Antignac</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Nephronophthisis.</article-title>
            <source>Curr Opin Genet Dev</source>
            <year>2005</year>
            <month>Jun</month>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>324</fpage>
            <page-range>324-31</page-range>
            <pub-id pub-id-type="pmid">15917209</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torres</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Autosomal dominant polycystic kidney disease: the last 3 years.</article-title>
            <source>Kidney Int</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>76</volume>
            <issue>2</issue>
            <fpage>149</fpage>
            <page-range>149-68</page-range>
            <pub-id pub-id-type="pmid">19455193</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xue</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mei</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Polycystic Kidney Disease and Renal Fibrosis.</article-title>
            <source>Adv Exp Med Biol</source>
            <year>2019</year>
            <volume>1165</volume>
            <fpage>81</fpage>
            <page-range>81-100</page-range>
            <pub-id pub-id-type="pmid">31399962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gast</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Marinaki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Arenas-Hernandez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Seaby</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Pengelly</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Gale</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Connor</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Bunyan</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Hoda&#x00148;ov&#x000e1;</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>&#x0017d;ivn&#x000e1;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kmoch</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ennis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Venkat-Raman</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Autosomal dominant tubulointerstitial kidney disease-UMOD is the most frequent non polycystic genetic kidney disease.</article-title>
            <source>BMC Nephrol</source>
            <year>2018</year>
            <month>Oct</month>
            <day>30</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>301</fpage>
            <pub-id pub-id-type="pmid">30376835</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r33">
          <label>33</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Shamam</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Hashmi</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <chapter-title>Autosomal Dominant Tubulointerstitial Kidney Disease</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">33760469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ishikawa</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Uremic acquired renal cystic disease. Natural history and complications.</article-title>
            <source>Nephron</source>
            <year>1991</year>
            <volume>58</volume>
            <issue>3</issue>
            <fpage>257</fpage>
            <page-range>257-67</page-range>
            <pub-id pub-id-type="pmid">1896090</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dell</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>The role of cilia in the pathogenesis of cystic kidney disease.</article-title>
            <source>Curr Opin Pediatr</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>212</fpage>
            <page-range>212-8</page-range>
            <pub-id pub-id-type="pmid">25575298</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hildebrandt</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Attanasio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Otto</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Nephronophthisis: disease mechanisms of a ciliopathy.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>23</fpage>
            <page-range>23-35</page-range>
            <pub-id pub-id-type="pmid">19118152</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fliegauf</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Benzing</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Omran</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>When cilia go bad: cilia defects and ciliopathies.</article-title>
            <source>Nat Rev Mol Cell Biol</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>8</volume>
            <issue>11</issue>
            <fpage>880</fpage>
            <page-range>880-93</page-range>
            <pub-id pub-id-type="pmid">17955020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilson</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Goilav</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Cystic disease of the kidney.</article-title>
            <source>Annu Rev Pathol</source>
            <year>2007</year>
            <volume>2</volume>
            <fpage>341</fpage>
            <page-range>341-68</page-range>
            <pub-id pub-id-type="pmid">18039103</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McConnachie</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Stow</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Mallett</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Ciliopathies and the Kidney: A Review.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>77</volume>
            <issue>3</issue>
            <fpage>410</fpage>
            <page-range>410-419</page-range>
            <pub-id pub-id-type="pmid">33039432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x0017d;ivn&#x000e1;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kidd</surname>
                <given-names>KO</given-names>
              </name>
              <name>
                <surname>Bare&#x00161;ov&#x000e1;</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>H&#x0016f;lkov&#x000e1;</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kmoch</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bleyer</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Autosomal dominant tubulointerstitial kidney disease: A review.</article-title>
            <source>Am J Med Genet C Semin Med Genet</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>190</volume>
            <issue>3</issue>
            <fpage>309</fpage>
            <page-range>309-324</page-range>
            <pub-id pub-id-type="pmid">36250282</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r41">
          <label>41</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>W&#x000fc;thrich</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Kistler</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kapoor</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mei</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <chapter-title>Blood Pressure Control for Polycystic Kidney Disease</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <source>Polycystic Kidney Disease [Internet]</source>
            <publisher-name>Codon Publications</publisher-name>
            <publisher-loc>Brisbane (AU)</publisher-loc>
            <year>2015</year>
            <month>11</month>
            <pub-id pub-id-type="pmid">27512778</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chapman</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gabow</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Schrier</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease.</article-title>
            <source>N Engl J Med</source>
            <year>1990</year>
            <month>Oct</month>
            <day>18</day>
            <volume>323</volume>
            <issue>16</issue>
            <fpage>1091</fpage>
            <page-range>1091-6</page-range>
            <pub-id pub-id-type="pmid">2215576</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torres</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of Disease: autosomal dominant and recessive polycystic kidney diseases.</article-title>
            <source>Nat Clin Pract Nephrol</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>40</fpage>
            <page-range>40-55; quiz 55</page-range>
            <pub-id pub-id-type="pmid">16932388</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reiterov&#x000e1;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tesa&#x00159;</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Autosomal Dominant Polycystic Kidney Disease: From Pathophysiology of Cystogenesis to Advances in the Treatment.</article-title>
            <source>Int J Mol Sci</source>
            <year>2022</year>
            <month>Mar</month>
            <day>19</day>
            <volume>23</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">35328738</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torres</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Pirson</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Autosomal dominant polycystic kidney disease.</article-title>
            <source>Lancet</source>
            <year>2007</year>
            <month>Apr</month>
            <day>14</day>
            <volume>369</volume>
            <issue>9569</issue>
            <fpage>1287</fpage>
            <page-range>1287-1301</page-range>
            <pub-id pub-id-type="pmid">17434405</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hartung</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Guay-Woodford</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Autosomal recessive polycystic kidney disease: a hepatorenal fibrocystic disorder with pleiotropic effects.</article-title>
            <source>Pediatrics</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>134</volume>
            <issue>3</issue>
            <fpage>e833</fpage>
            <page-range>e833-45</page-range>
            <pub-id pub-id-type="pmid">25113295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guay-Woodford</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Desmond</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Autosomal recessive polycystic kidney disease: the clinical experience in North America.</article-title>
            <source>Pediatrics</source>
            <year>2003</year>
            <month>May</month>
            <volume>111</volume>
            <issue>5 Pt 1</issue>
            <fpage>1072</fpage>
            <page-range>1072-80</page-range>
            <pub-id pub-id-type="pmid">12728091</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bergmann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Senderek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Windelen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>K&#x000fc;pper</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Middeldorf</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dornia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rudnik-Sch&#x000f6;neborn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Konrad</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schmitt</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Seeman</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Neuhaus</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Vester</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kirfel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>B&#x000fc;ttner</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zerres</surname>
                <given-names>K</given-names>
              </name>
              <collab>APN (Arbeitsgemeinschaft f&#x000fc;r P&#x000e4;diatrische Nephrologie)</collab>
            </person-group>
            <article-title>Clinical consequences of PKHD1 mutations in 164 patients with autosomal-recessive polycystic kidney disease (ARPKD).</article-title>
            <source>Kidney Int</source>
            <year>2005</year>
            <month>Mar</month>
            <volume>67</volume>
            <issue>3</issue>
            <fpage>829</fpage>
            <page-range>829-48</page-range>
            <pub-id pub-id-type="pmid">15698423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r49">
          <label>49</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Burgmaier</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gimpel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Liebau</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Autosomal Recessive Polycystic Kidney Disease&#x000a0;&#x02013;&#x000a0;<italic>PKHD1</italic></chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source>
            <publisher-name>University of Washington, Seattle</publisher-name>
            <publisher-loc>Seattle (WA)</publisher-loc>
            <year>2001</year>
            <month>7</month>
            <day>19</day>
            <pub-id pub-id-type="pmid">20301501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chinali</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lucchetti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ricotta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Esposito</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>D'Anna</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rinelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Emma</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Massella</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Cardiac Abnormalities in Children with Autosomal Recessive Polycystic Kidney Disease.</article-title>
            <source>Cardiorenal Med</source>
            <year>2019</year>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>180</fpage>
            <page-range>180-189</page-range>
            <pub-id pub-id-type="pmid">30844805</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hartung</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Matheson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lande</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Dell</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Guay-Woodford</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Gerson</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Warady</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Hooper</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Furth</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Neurocognition in children with autosomal recessive polycystic kidney disease in the CKiD cohort study.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>29</volume>
            <issue>10</issue>
            <fpage>1957</fpage>
            <page-range>1957-65</page-range>
            <pub-id pub-id-type="pmid">24828609</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wataya-Kaneda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hamasaki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Katayama</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Trends in the prevalence of tuberous sclerosis complex manifestations: an epidemiological study of 166 Japanese patients.</article-title>
            <source>PLoS One</source>
            <year>2013</year>
            <volume>8</volume>
            <issue>5</issue>
            <fpage>e63910</fpage>
            <pub-id pub-id-type="pmid">23691114</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r53">
          <label>53</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Mikhail</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <chapter-title>Von Hippel-Lindau Syndrome</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>1</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">29083737</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aufforth</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Ramakant</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sadowski</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Trebska-McGowan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nilubol</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pacak</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kebebew</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Pheochromocytoma Screening Initiation and Frequency in von Hippel-Lindau Syndrome.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>100</volume>
            <issue>12</issue>
            <fpage>4498</fpage>
            <page-range>4498-504</page-range>
            <pub-id pub-id-type="pmid">26451910</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r55">
          <label>55</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Garfield</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <chapter-title>Simple Renal Cyst</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>28</day>
            <pub-id pub-id-type="pmid">29763075</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r56">
          <label>56</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Sigmon</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Shikhman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nielson</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <chapter-title>Renal Cyst (Archived)</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>12</month>
            <day>27</day>
            <pub-id pub-id-type="pmid">29261909</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Erlich</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lipsky</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Braga</surname>
                <given-names>LH</given-names>
              </name>
            </person-group>
            <article-title>A meta-analysis of the incidence and fate of contralateral vesicoureteral reflux in unilateral multicystic dysplastic kidney.</article-title>
            <source>J Pediatr Urol</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>77.e1</fpage>
            <page-range>77.e1-77.e7</page-range>
            <pub-id pub-id-type="pmid">30482499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Srivastava</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Autosomal dominant polycystic kidney disease.</article-title>
            <source>Am Fam Physician</source>
            <year>2014</year>
            <month>Sep</month>
            <day>01</day>
            <volume>90</volume>
            <issue>5</issue>
            <fpage>303</fpage>
            <page-range>303-7</page-range>
            <pub-id pub-id-type="pmid">25251090</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gaur</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gedroyc</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>ADPKD-what the radiologist should know.</article-title>
            <source>Br J Radiol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>92</volume>
            <issue>1098</issue>
            <fpage>20190078</fpage>
            <pub-id pub-id-type="pmid">31039325</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Avni</surname>
                <given-names>FE</given-names>
              </name>
              <name>
                <surname>Garel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cassart</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>D'Haene</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Riccabona</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Imaging and classification of congenital cystic renal diseases.</article-title>
            <source>AJR Am J Roentgenol</source>
            <year>2012</year>
            <month>May</month>
            <volume>198</volume>
            <issue>5</issue>
            <fpage>1004</fpage>
            <page-range>1004-13</page-range>
            <pub-id pub-id-type="pmid">22528889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rajanna</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Srinivas</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Aneja</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Autosomal recessive polycystic kidney disease: antenatal diagnosis and histopathological correlation.</article-title>
            <source>J Clin Imaging Sci</source>
            <year>2013</year>
            <volume>3</volume>
            <fpage>13</fpage>
            <pub-id pub-id-type="pmid">23814685</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Israel</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Bosniak</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>An update of the Bosniak renal cyst classification system.</article-title>
            <source>Urology</source>
            <year>2005</year>
            <month>Sep</month>
            <volume>66</volume>
            <issue>3</issue>
            <fpage>484</fpage>
            <page-range>484-8</page-range>
            <pub-id pub-id-type="pmid">16140062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silverman</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Pedrosa</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Hindman</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Schieda</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Remer</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Shinagare</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Curci</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Raman</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Kaffenberger</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>ZJ</given-names>
              </name>
              <name>
                <surname>Chandarana</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Davenport</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Bosniak Classification of Cystic Renal Masses, Version 2019: An Update Proposal and Needs Assessment.</article-title>
            <source>Radiology</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>292</volume>
            <issue>2</issue>
            <fpage>475</fpage>
            <page-range>475-488</page-range>
            <pub-id pub-id-type="pmid">31210616</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gimpel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Avni</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Breysem</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Burgmaier</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Caroli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cetiner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Haffner</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hartung</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Franke</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>K&#x000f6;nig</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liebau</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Mekahli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ong</surname>
                <given-names>ACM</given-names>
              </name>
              <name>
                <surname>Pape</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Titieni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Torra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Winyard</surname>
                <given-names>PJD</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Imaging of Kidney Cysts and Cystic Kidney Diseases in Children: An International Working Group Consensus Statement.</article-title>
            <source>Radiology</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>290</volume>
            <issue>3</issue>
            <fpage>769</fpage>
            <page-range>769-782</page-range>
            <pub-id pub-id-type="pmid">30599104</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gunay-Aygun</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Font-Montgomery</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lukose</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tuchman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Graf</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bryant</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Kleta</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Piwnica-Worms</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bernardini</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Krasnewich</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Oden</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ling</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Quezado</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zak</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Daryanani</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Turkbey</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Choyke</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Guay-Woodford</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Gahl</surname>
                <given-names>WA</given-names>
              </name>
            </person-group>
            <article-title>Correlation of kidney function, volume and imaging findings, and PKHD1 mutations in 73 patients with autosomal recessive polycystic kidney disease.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>5</volume>
            <issue>6</issue>
            <fpage>972</fpage>
            <page-range>972-84</page-range>
            <pub-id pub-id-type="pmid">20413436</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Irazabal</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Abebe</surname>
                <given-names>KZ</given-names>
              </name>
              <name>
                <surname>Bae</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Perrone</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Schrier</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Steinman</surname>
                <given-names>TI</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Flessner</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>VE</given-names>
              </name>
              <collab>HALT Investigators</collab>
            </person-group>
            <article-title>Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2017</year>
            <month>Nov</month>
            <day>01</day>
            <volume>32</volume>
            <issue>11</issue>
            <fpage>1857</fpage>
            <page-range>1857-1865</page-range>
            <pub-id pub-id-type="pmid">27484667</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torres</surname>
                <given-names>VE</given-names>
              </name>
            </person-group>
            <article-title>Salt, water, and vasopressin in&#x000a0;polycystic kidney disease.</article-title>
            <source>Kidney Int</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>98</volume>
            <issue>4</issue>
            <fpage>831</fpage>
            <page-range>831-834</page-range>
            <pub-id pub-id-type="pmid">32998813</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torres</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Bankir</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Grantham</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>A case for water in the treatment of polycystic kidney disease.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>4</volume>
            <issue>6</issue>
            <fpage>1140</fpage>
            <page-range>1140-50</page-range>
            <pub-id pub-id-type="pmid">19443627</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barash</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ponda</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Goldfarb</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Skolnik</surname>
                <given-names>EY</given-names>
              </name>
            </person-group>
            <article-title>A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>693</fpage>
            <page-range>693-7</page-range>
            <pub-id pub-id-type="pmid">20167686</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kramers</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Koorevaar</surname>
                <given-names>IW</given-names>
              </name>
              <name>
                <surname>Drenth</surname>
                <given-names>JPH</given-names>
              </name>
              <name>
                <surname>de Fijter</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Neto</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>DJM</given-names>
              </name>
              <name>
                <surname>Vart</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wetzels</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Zietse</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gansevoort</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Meijer</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Salt, but not protein intake, is associated with accelerated disease progression in autosomal dominant polycystic kidney disease.</article-title>
            <source>Kidney Int</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>98</volume>
            <issue>4</issue>
            <fpage>989</fpage>
            <page-range>989-998</page-range>
            <pub-id pub-id-type="pmid">32534051</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torres</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Abebe</surname>
                <given-names>KZ</given-names>
              </name>
              <name>
                <surname>Schrier</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Perrone</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Steinman</surname>
                <given-names>TI</given-names>
              </name>
              <name>
                <surname>Brosnahan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hogan</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Rahbari</surname>
                <given-names>FF</given-names>
              </name>
              <name>
                <surname>Grantham</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Bae</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Flessner</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>Dietary salt restriction is beneficial to the management of autosomal dominant polycystic&#x000a0;kidney disease.</article-title>
            <source>Kidney Int</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>91</volume>
            <issue>2</issue>
            <fpage>493</fpage>
            <page-range>493-500</page-range>
            <pub-id pub-id-type="pmid">27993381</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torres</surname>
                <given-names>VE</given-names>
              </name>
            </person-group>
            <article-title>Pro: Tolvaptan delays the progression of autosomal dominant polycystic kidney disease.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2019</year>
            <month>Jan</month>
            <day>01</day>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>30</fpage>
            <page-range>30-34</page-range>
            <pub-id pub-id-type="pmid">30312438</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Masuda</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shimizu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sekine</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Okato</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hou</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Suyama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Araki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kojima</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Naya</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of Tolvaptan for Patients With Autosomal Dominant Polycystic Kidney Disease in Real-world Practice: A Single Institution Retrospective Study.</article-title>
            <source>In Vivo</source>
            <year>2023</year>
            <season>Mar-Apr</season>
            <volume>37</volume>
            <issue>2</issue>
            <fpage>801</fpage>
            <page-range>801-805</page-range>
            <pub-id pub-id-type="pmid">36881088</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhou</surname>
                <given-names>JX</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>VE</given-names>
              </name>
            </person-group>
            <article-title>Drug repurposing in autosomal dominant polycystic kidney disease.</article-title>
            <source>Kidney Int</source>
            <year>2023</year>
            <month>May</month>
            <volume>103</volume>
            <issue>5</issue>
            <fpage>859</fpage>
            <page-range>859-871</page-range>
            <pub-id pub-id-type="pmid">36870435</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raina</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Houry</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rath</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mangat</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pandher</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Islam</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khattab</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Kalout</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Bagga</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Clinical Utility and Tolerability of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).</article-title>
            <source>Drug Healthc Patient Saf</source>
            <year>2022</year>
            <volume>14</volume>
            <fpage>147</fpage>
            <page-range>147-159</page-range>
            <pub-id pub-id-type="pmid">36105663</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>RU</given-names>
              </name>
              <name>
                <surname>Messchendorp</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Birn</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Capasso</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cornec-Le Gall</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Devuyst</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>van Eerde</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guirchoun</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hoorn</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Knoers</surname>
                <given-names>NVAM</given-names>
              </name>
              <name>
                <surname>Korst</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Mekahli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Le Meur</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nijenhuis</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ong</surname>
                <given-names>ACM</given-names>
              </name>
              <name>
                <surname>Sayer</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Servais</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tesar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Torra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Gansevoort</surname>
                <given-names>RT</given-names>
              </name>
            </person-group>
            <article-title>An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2022</year>
            <month>Apr</month>
            <day>25</day>
            <volume>37</volume>
            <issue>5</issue>
            <fpage>825</fpage>
            <page-range>825-839</page-range>
            <pub-id pub-id-type="pmid">35134221</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chebib</surname>
                <given-names>FT</given-names>
              </name>
              <name>
                <surname>Perrone</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Dahl</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Mrug</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mustafa</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Rastogi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Watnick</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>ASL</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>VE</given-names>
              </name>
            </person-group>
            <article-title>A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>29</volume>
            <issue>10</issue>
            <fpage>2458</fpage>
            <page-range>2458-2470</page-range>
            <pub-id pub-id-type="pmid">30228150</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guay-Woodford</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Bissler</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Bockenhauer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cadnapaphornchai</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Dell</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Kerecuk</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Liebau</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Alonso-Peclet</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Shneider</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Emre</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Heller</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kamath</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Moise</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Eichenwald</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Keller</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Wilkins-Haug</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bergmann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gunay-Aygun</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hooper</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Hardy</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Hartung</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Streisand</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Perrone</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Moxey-Mims</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Consensus expert recommendations for the diagnosis and management of autosomal recessive polycystic kidney disease: report of an international conference.</article-title>
            <source>J Pediatr</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>165</volume>
            <issue>3</issue>
            <fpage>611</fpage>
            <page-range>611-7</page-range>
            <pub-id pub-id-type="pmid">25015577</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mekahli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Liebau</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Cadnapaphornchai</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Greenbaum</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Litwin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Seeman</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Guay-Woodford</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Design of two ongoing clinical trials of tolvaptan in the treatment of pediatric patients with autosomal recessive polycystic kidney disease.</article-title>
            <source>BMC Nephrol</source>
            <year>2023</year>
            <month>Feb</month>
            <day>13</day>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>33</fpage>
            <pub-id pub-id-type="pmid">36782137</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwarz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vatandaslar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Merkel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Haller</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Renal cell carcinoma in transplant recipients with acquired cystic kidney disease.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2007</year>
            <month>Jul</month>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>750</fpage>
            <page-range>750-6</page-range>
            <pub-id pub-id-type="pmid">17699492</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Emre</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Turgay</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Murat</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ozg&#x000fc;r</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cankon</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>'Stepped procedure' in laparoscopic cyst decortication during the learning period of laparoscopic surgery: Detailed evaluation of initial experiences.</article-title>
            <source>J Minim Access Surg</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>37</fpage>
            <page-range>37-41</page-range>
            <pub-id pub-id-type="pmid">20814509</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r82">
          <label>82</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsukamoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Urate</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yamada</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Azushima</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamaji</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kinguchi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Uneda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kanaoka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wakui</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tamura</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Comparative Efficacy of Pharmacological Treatments for Adults With Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.</article-title>
            <source>Front Pharmacol</source>
            <year>2022</year>
            <volume>13</volume>
            <fpage>885457</fpage>
            <pub-id pub-id-type="pmid">35662736</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r83">
          <label>83</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richards</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Modarage</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Malik</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Goggolidou</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>The cellular pathways and potential therapeutics of Polycystic Kidney Disease.</article-title>
            <source>Biochem Soc Trans</source>
            <year>2021</year>
            <month>Jun</month>
            <day>30</day>
            <volume>49</volume>
            <issue>3</issue>
            <fpage>1171</fpage>
            <page-range>1171-1188</page-range>
            <pub-id pub-id-type="pmid">34156429</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r84">
          <label>84</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Woo</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Miao</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Pelayo</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Woolf</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Taxol inhibits progression of congenital polycystic kidney disease.</article-title>
            <source>Nature</source>
            <year>1994</year>
            <month>Apr</month>
            <day>21</day>
            <volume>368</volume>
            <issue>6473</issue>
            <fpage>750</fpage>
            <page-range>750-3</page-range>
            <pub-id pub-id-type="pmid">7908721</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r85">
          <label>85</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gile</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Cowley</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Gattone</surname>
                <given-names>VH</given-names>
              </name>
              <name>
                <surname>O'Donnell</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Swan</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Grantham</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Effect of lovastatin on the development of polycystic kidney disease in the Han:SPRD rat.</article-title>
            <source>Am J Kidney Dis</source>
            <year>1995</year>
            <month>Sep</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>501</fpage>
            <page-range>501-7</page-range>
            <pub-id pub-id-type="pmid">7645559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r86">
          <label>86</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Omori</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hida</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fujita</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tanimura</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kohno</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Awazu</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>1604</fpage>
            <page-range>1604-14</page-range>
            <pub-id pub-id-type="pmid">16641154</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r87">
          <label>87</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jamal</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Nunes</surname>
                <given-names>ACF</given-names>
              </name>
              <name>
                <surname>Vaziri</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Ramchandran</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bacallao</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Nauli</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Nauli</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Rapamycin treatment correlates changes in primary cilia expression with cell cycle regulation in epithelial cells.</article-title>
            <source>Biochem Pharmacol</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>178</volume>
            <fpage>114056</fpage>
            <pub-id pub-id-type="pmid">32470549</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r88">
          <label>88</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wahl</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Serra</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Le Hir</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Molle</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>W&#x000fc;thrich</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>21</volume>
            <issue>3</issue>
            <fpage>598</fpage>
            <page-range>598-604</page-range>
            <pub-id pub-id-type="pmid">16221708</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r89">
          <label>89</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schrier</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Edelstein</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2005</year>
            <month>Jan</month>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>46</fpage>
            <page-range>46-51</page-range>
            <pub-id pub-id-type="pmid">15563559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r90">
          <label>90</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xue</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mei</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>SQ</given-names>
              </name>
            </person-group>
            <article-title>Effect of Statins on Renal Function and Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease.</article-title>
            <source>Kidney Dis (Basel)</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>6</volume>
            <issue>6</issue>
            <fpage>407</fpage>
            <page-range>407-413</page-range>
            <pub-id pub-id-type="pmid">33313061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r91">
          <label>91</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hogan</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Masyuk</surname>
                <given-names>TV</given-names>
              </name>
            </person-group>
            <article-title>Concurrent Targeting of Vasopressin Receptor 2 and Somatostatin Receptors in Autosomal Dominant Polycystic Kidney Disease: A Promising Approach for Autosomal Dominant Polycystic Kidney Disease Treatment?</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2023</year>
            <month>Feb</month>
            <day>01</day>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>154</fpage>
            <page-range>154-156</page-range>
            <pub-id pub-id-type="pmid">36754002</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r92">
          <label>92</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Capuano</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Buonanno</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Riccio</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rizzo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pisani</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Tolvaptan vs. somatostatin in the treatment of ADPKD: A review of the literature.</article-title>
            <source>Clin Nephrol</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>97</volume>
            <issue>3</issue>
            <fpage>131</fpage>
            <page-range>131-140</page-range>
            <pub-id pub-id-type="pmid">34846296</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r93">
          <label>93</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jing</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mei</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Qi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mei</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Triptolide delays disease progression in an adult rat model of polycystic kidney disease through the JAK2-STAT3 pathway.</article-title>
            <source>Am J Physiol Renal Physiol</source>
            <year>2018</year>
            <month>Sep</month>
            <day>01</day>
            <volume>315</volume>
            <issue>3</issue>
            <fpage>F479</fpage>
            <page-range>F479-F486</page-range>
            <pub-id pub-id-type="pmid">29513074</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r94">
          <label>94</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seliger</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Watnick</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Althouse</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Perrone</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Abebe</surname>
                <given-names>KZ</given-names>
              </name>
              <name>
                <surname>Hallows</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Miskulin</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Bae</surname>
                <given-names>KT</given-names>
              </name>
            </person-group>
            <article-title>Baseline Characteristics and Patient-Reported Outcomes of ADPKD Patients in the Multicenter TAME-PKD Clinical Trial.</article-title>
            <source>Kidney360</source>
            <year>2020</year>
            <month>Dec</month>
            <day>31</day>
            <volume>1</volume>
            <issue>12</issue>
            <fpage>1363</fpage>
            <page-range>1363-1372</page-range>
            <pub-id pub-id-type="pmid">33768205</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r95">
          <label>95</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pastor-Soler</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pham</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rivera</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>PY</given-names>
              </name>
              <name>
                <surname>Mancino</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Saitta</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hallows</surname>
                <given-names>KR</given-names>
              </name>
            </person-group>
            <article-title>Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model.</article-title>
            <source>Am J Physiol Renal Physiol</source>
            <year>2022</year>
            <month>Jan</month>
            <day>01</day>
            <volume>322</volume>
            <issue>1</issue>
            <fpage>F27</fpage>
            <page-range>F27-F41</page-range>
            <pub-id pub-id-type="pmid">34806449</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r96">
          <label>96</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leonhard</surname>
                <given-names>WN</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Kanhai</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Iliuta</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Bozovic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>DJM</given-names>
              </name>
              <name>
                <surname>Pei</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease.</article-title>
            <source>EBioMedicine</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>47</volume>
            <fpage>436</fpage>
            <page-range>436-445</page-range>
            <pub-id pub-id-type="pmid">31473186</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r97">
          <label>97</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Belibi</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Yamaguchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Christensen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reif</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Grantham</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>The effect of caffeine on renal epithelial cells from patients with autosomal dominant polycystic kidney disease.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2002</year>
            <month>Nov</month>
            <volume>13</volume>
            <issue>11</issue>
            <fpage>2723</fpage>
            <page-range>2723-9</page-range>
            <pub-id pub-id-type="pmid">12397042</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r98">
          <label>98</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grantham</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Uchic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cragoe</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Kornhaus</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Grantham</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Donoso</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mangoo-Karim</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Evan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McAteer</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Chemical modification of cell proliferation and fluid secretion in renal cysts.</article-title>
            <source>Kidney Int</source>
            <year>1989</year>
            <month>Jun</month>
            <volume>35</volume>
            <issue>6</issue>
            <fpage>1379</fpage>
            <page-range>1379-89</page-range>
            <pub-id pub-id-type="pmid">2770116</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r99">
          <label>99</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tesar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ciechanowski</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pei</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Barash</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Shannon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Levisetti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Arkin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Serra</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>28</volume>
            <issue>11</issue>
            <fpage>3404</fpage>
            <page-range>3404-3413</page-range>
            <pub-id pub-id-type="pmid">28838955</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r100">
          <label>100</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grantham</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Guay-Woodford</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Bae</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Wetzel</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Baumgarten</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Kenney</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Klahr</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Hirschman</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Meyers</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>JP</given-names>
              </name>
              <collab>CRISP Investigators</collab>
            </person-group>
            <article-title>Volume progression in polycystic kidney disease.</article-title>
            <source>N Engl J Med</source>
            <year>2006</year>
            <month>May</month>
            <day>18</day>
            <volume>354</volume>
            <issue>20</issue>
            <fpage>2122</fpage>
            <page-range>2122-30</page-range>
            <pub-id pub-id-type="pmid">16707749</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r101">
          <label>101</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ars</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bernis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fraga</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Martins</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ortiz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez-P&#x000e9;rez</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Sans</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Torra</surname>
                <given-names>R</given-names>
              </name>
              <collab>Spanish Working Group on Inherited Kidney Disease</collab>
            </person-group>
            <article-title>Spanish guidelines for the management of autosomal dominant polycystic kidney disease.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>29 Suppl 4</volume>
            <fpage>iv95</fpage>
            <page-range>iv95-105</page-range>
            <pub-id pub-id-type="pmid">25165191</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r102">
          <label>102</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cornec-Le Gall</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Audr&#x000e9;zet</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Hourmant</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Morin</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Perrichot</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Charasse</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Whebe</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Renaudineau</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jousset</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Guillodo</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Grall-Jezequel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saliou</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>F&#x000e9;rec</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Le Meur</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Type of PKD1 mutation influences renal outcome in ADPKD.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2013</year>
            <month>May</month>
            <volume>24</volume>
            <issue>6</issue>
            <fpage>1006</fpage>
            <page-range>1006-13</page-range>
            <pub-id pub-id-type="pmid">23431072</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r103">
          <label>103</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murphy</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Dai</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Blount</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Droher</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Liberti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Crews</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Dahl</surname>
                <given-names>NK</given-names>
              </name>
            </person-group>
            <article-title>Revisiting racial differences in ESRD due to ADPKD in the United States.</article-title>
            <source>BMC Nephrol</source>
            <year>2019</year>
            <month>Feb</month>
            <day>14</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>55</fpage>
            <pub-id pub-id-type="pmid">30764782</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r104">
          <label>104</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Woon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bielinski-Bradbury</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>O'Reilly</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease.</article-title>
            <source>BMC Nephrol</source>
            <year>2015</year>
            <month>Aug</month>
            <day>15</day>
            <volume>16</volume>
            <fpage>140</fpage>
            <pub-id pub-id-type="pmid">26275819</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r105">
          <label>105</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reed</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Helal</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>McFann</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>XD</given-names>
              </name>
              <name>
                <surname>Schrier</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>The impact of type II diabetes mellitus in patients with autosomal dominant polycystic kidney disease.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>27</volume>
            <issue>7</issue>
            <fpage>2862</fpage>
            <page-range>2862-5</page-range>
            <pub-id pub-id-type="pmid">22207329</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r106">
          <label>106</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Niemczyk</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gradzik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Niemczyk</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bujko</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Go&#x00142;&#x00119;biowski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>P&#x00105;czek</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Intracranial aneurysms in autosomal dominant polycystic kidney disease.</article-title>
            <source>AJNR Am J Neuroradiol</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>34</volume>
            <issue>8</issue>
            <fpage>1556</fpage>
            <page-range>1556-9</page-range>
            <pub-id pub-id-type="pmid">23449651</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r107">
          <label>107</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gimpel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bergmann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bockenhauer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Breysem</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cadnapaphornchai</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Cetiner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dudley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Emma</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Konrad</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>K&#x000f6;nig</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liebau</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Marlais</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mekahli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Metcalfe</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Perrone</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Sinha</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Titieni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Torra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Winyard</surname>
                <given-names>PJD</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people.</article-title>
            <source>Nat Rev Nephrol</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>15</volume>
            <issue>11</issue>
            <fpage>713</fpage>
            <page-range>713-726</page-range>
            <pub-id pub-id-type="pmid">31118499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r108">
          <label>108</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cornec-Le Gall</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Alam</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Perrone</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Autosomal dominant polycystic kidney disease.</article-title>
            <source>Lancet</source>
            <year>2019</year>
            <month>Mar</month>
            <day>02</day>
            <volume>393</volume>
            <issue>10174</issue>
            <fpage>919</fpage>
            <page-range>919-935</page-range>
            <pub-id pub-id-type="pmid">30819518</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r109">
          <label>109</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Odedra</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sabongui</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khalili</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schieda</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pei</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Krishna</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Autosomal Dominant Polycystic Kidney Disease: Role of Imaging in Diagnosis and Management.</article-title>
            <source>Radiographics</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>e220126</fpage>
            <pub-id pub-id-type="pmid">36459494</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r110">
          <label>110</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bae</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Tao</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>ASL</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Perrone</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Brosnahan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Steinman</surname>
                <given-names>TI</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Mrug</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Srivastava</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Landsittel</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Abebe</surname>
                <given-names>KZ</given-names>
              </name>
              <collab>CRISP and HALT PKD Consortium</collab>
            </person-group>
            <article-title>Volume Progression and Imaging Classification of Polycystic Liver in Early Autosomal Dominant Polycystic Kidney Disease.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>374</fpage>
            <page-range>374-384</page-range>
            <pub-id pub-id-type="pmid">35217526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20210.r111">
          <label>111</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pisani</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Giacosa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Giuliotti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moretto</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Regolisti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cantarelli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vaglio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fiaccadori</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Manenti</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Ultrasound to address medullary sponge kidney: a retrospective study.</article-title>
            <source>BMC Nephrol</source>
            <year>2020</year>
            <month>Oct</month>
            <day>12</day>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>430</fpage>
            <pub-id pub-id-type="pmid">33046028</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
